The feasibility of SmART (small animal radiation therapy) platform for delivering complex dose distributions by Verde, Joana Batista
  
 
 
UNIVERSIDADE DE LISBOA  
FACULDADE DE CIENCIAS 
 DEPARTAMENTO DE FÍSICA 
 
 
 
 
 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for 
Delivering Complex Dose Distributions 
 
 
Joana Batista Verde 
 
 
Mestrado Integrado em Engenharia Biomédica e Biofísica 
Perfil em Radiações em Diagnóstico e Terapia 
 
Dissertação orientada por: 
 Professor Frank Verhaegen e Professor Luís Peralta 
 
 
[2016] 
  
2015/2016 
 
ii 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for Delivering Complex Dose Distribution 
ACKNOWLEDGEMENTS 
Hereby, I would like to address my gratitude to all the people who helped me to perform my 
master´s project, write this thesis, and who made the last year at MAASTRO Clinic such a great 
time. First and foremost, I would like to express my gratitude to both my external supervisors. 
My sincere thanks to Dr. Frank Verhaegen, head of physics research at MAASTRO Clinic, for 
giving me the opportunity to be a part of his exciting research division, by engaging me in new 
ideas and demanding a high quality of work. I am extremely thankful to Stefan van Hoof for 
being always there to listen and give advices, for his patience, motivation, enthusiasm, and 
immense knowledge. I am also grateful to him for the long discussions that helped me sort out 
the technical details of my work and for the encouragement to use the correct grammar and 
consistent notation in my writings.  
I wish to thank Professor Luís Peralta for being my internal supervisor and for all the support 
through this learning process. 
Special thanks to Isabel de Almeida for the laughing moments together and all the funny stories. 
Another special thanks to Lotte Scyns for all her useful advice, her help with measurements and 
also for her enthusiastic support to Cristiano Ronaldo and to the National Portuguese team. My 
profound gratitude to the whole research group of MAASRO Clinic with whom I had the privilege 
to work and who I have not already mentioned: Matilde Costa, Mark Podesta, Gabriel Fonseca, 
Murillo, Ruben, Janita, Sara, Brent, Timo, Jurgen, Ivonka, Shane, Shaun, Aniek, Guacomo, Cecile 
and Ana Vaniqui. They provided a friendly and cooperative atmosphere at work and 
entertainment during lunch and coffee breaks. 
My deepest sincere thanks to Mariana Brás for all the support during this journey, as well as for 
her patience, help and laughs who made my days easier. 
I am very grateful to the Professors of the Institute of Biophysics and Biomedical Engineering for 
all the dedication, time, encouragement and knowledge that they shared with me during the last 
ﬁve years. 
To my friends and roommates, thank you for listening, offering me advice, and supporting me 
through this entire process, thank you for the phone calls, e-mails, texts, editing advice, and 
especially for being there whenever I needed. 
Most importantly, none of this would have been possible without the love and patience of my 
family. My immediate family to whom this dissertation is dedicated to, has been a constant 
source of love, concern, support and strength all these years. Thus, I would like to express my 
heart-felt gratitude to them. They supported and encouraged me throughout this endeavor and, 
therefore I warmly appreciate their unconditional generosity and understanding. 
  
2015/2016 
 
iii 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for Delivering Complex Dose Distribution 
RESUMO 
O cancro é atualmente a segunda principal causa de morte na Europa, encontrando-se apenas 
atrás das doenças cardiovasculares. O cancro surge quando as células normais se começam a 
transformar em células cancerígenas. Isto é, quando as células adquirem a capacidade de se 
multiplicarem e invadirem os tecidos e outros órgãos. Na União Europeia, uma previsão 
realizada pela International Agency for Research on Cancer (IARC), e tendo como base apenas o 
envelhecimento da população, aponta para um aumento de novos casos de cancro na ordem dos 
24 milhões até 2035.  
O tratamento eficaz do cancro deve dirigir-se não apenas ao tumor principal, mas também aos 
tumores que possam aparecer, por propagação. No combate contra o cancro existem atualmente 
diferentes tratamentos como a cirurgia, a radioterapia, a quimioterapia ou uma combinação 
destas diferentes técnicas. Hoje em dia cerca de 4 em cada 10 doentes oncológicos (40%) em 
alguma etapa do tratamento da sua doença, são submetidos a tratamentos de radioterapia. Esta 
é uma modalidade terapêutica utilizada sobretudo no tratamento de doenças oncológicas, que 
usa radiação ionizante como os raios X para lesar ou destruir as células dos tumores malignos. 
Consoante a localização da fonte de radiação em relação ao corpo do paciente podem existir 
duas formas da radioterapia: radioterapia interna, na qual a radiação tem origem a partir de 
uma fonte que é colocada no interior do organismo e radioterapia externa, na qual a fonte de 
radiação se encontra a uma certa distância do paciente, sendo gerada na sua maioria das vezes 
por aparelho chamado acelerador linear. 
Os tratamentos de radioterapia concentram-se na destruição das células tumorais, ao mesmo 
tempo que se concentram na necessidade de minimizar ao máximo a exposição dos tecidos sãos 
adjacentes à radiação. De maneira a ter tratamentos onde a radiação se restrinja cada vez mais 
ao tumor enquanto há uma minimização da exposição dos tecidos saudáveis adjacentes, novas 
técnicas de radioterapia têm aparecido ao longo das últimas décadas como são exemplo a 
radioterapia tridimensional conformal (3D-CRT), a radioterapia de intensidade modulada 
(IMRT), a radioterapia guiada por imagem (IGRT) entre outras.  
Uma validação experimental destas técnicas é crucial antes da sua implementação em ambiente 
clínico. Uma vez que é difícil validar novas técnicas com base em dados humanos, devido às 
preocupações práticas e éticas, a validação experimental baseada em pequenos animais 
apareceu como uma abordagem alternativa e mais rápida, o que faz da radioterapia em 
pequenos animais um campo de pesquisa ativo atualmente, provado pelo forte investimento e 
procura de plataformas de radioterapia para pequenos animais por parte de diferentes 
institutos. Este tipo de plataformas de radioterapia para pequenos animais tem também o valor 
acrescentado de permitir estudar e avaliar a eficácia de diferentes terapias anticancerígenas 
através do estudo de mecanismos de resposta das doenças cancerígenas. Estas plataformas são 
também importante para estudar a resposta dos tecidos cancerígenos e dos tecidos normais à 
exposição de radiação, assim como na avaliação da segurança de novos medicamentos 
anticancerígenos. 
Apesar do grande desenvolvimento e consequente aparecimento de diferentes plataformas de 
radioterapia para pequenos animais existe um fator limitante comum a todas elas. Atualmente 
neste tipo de plataformas os tratamentos baseiam-se principalmente em técnicas de irradiação 
primitivas. Nestas técnicas os tratamentos são baseados em um ou dois feixes estáticos de 
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radiação muitas vezes envolvendo uma irradiação total ou parcial do corpo, o que faz destes 
tratamentos uma abordagem nada representativa do que realmente acontece em ambiente 
clínico. Para que hajam tratamentos mais representativos e com configurações mais 
semelhantes ao que acontece em ambiente clínico, planos de tratamento mais complexos onde 
seja possível entregar distribuições de dose mais complexas e heterogéneas são necessários. 
Desta forma, o objetivo deste estudo é investigar a capacidade da plataforma de radioterapia 
para pequenos animais, XRAD-225Cx, de entregar distribuições de dose mais complexas através 
do movimento da mesa de tratamento e da gantry durante o tratamento. Adicionalmente , é 
também investigado a necessidade de graus de liberdade adicionais em radioterapia em 
pequeno animais através de simulações de tratamentos com diferentes configurações de feixes 
de radiação. 
A plataforma de radioterapia para pequenos animais utilizada neste estudo foi a plataforma 
Precision X-Ray XRAD-225Cx que se encontra instalada na MAASTRO Clinic (Maastricht, 
Holanda). No que diz respeito às simulações dos tratamentos, estas foram simuladas com 
recurso ao software, SmART-Plan, um sistema de plano de tratamento desenvolvido no 
departamento de radioterapia da MAASTRO Clinic. Este é um software desenvolvido em 
MATLAB baseado num algoritmo de Monte-Carlo. 
Distribuições de dose mais complexas podem ser conseguidas através do movimento simultâneo 
de mesa de radioterapia e da gantry durante o tratamento. A viabilidade desta técnica foi 
investigada através da utilização de planos de tratamento baseados em pontos de controlo, os 
quais são designados de protocolos. Um protocolo é um documento de texto estruturado onde 
estão descritas de uma forma sequencial as diferentes etapas e variáveis de um tratamento Um 
protocolo é dividido num número de feixes e cada feixe é dividido em pontos de controlo. Um 
ponto de controlo específica o comportamento da plataforma num momento específico de 
tempo, isto é, especifica a maneira como é que o tratamento é entregue. Em cada ponto de 
controlo pode ser especificado o posicionamento e movimento da mesa de radiação e da gantry, 
o ângulo e o sentido de rotação da gantry, a energia do feixe, o período de irradiação e a dose 
entregue em cada ponto de controlo.  
Nesta tese o posicionamento da mesa de tratamento foi verificado e avaliado através de um 
sensor de ultra-som. De maneira a avaliar o movimento da mesa de tratamento, protocolos com 
diferentes números de pontos de controlo foram testados. O movimento da mesa de tratamento 
foi avaliado ao longo das 3 direções do movimento, longitudinal, lateral e vertical. Depois de uma 
correta avaliação do movimento da mesa de tratamento, os tratamentos baseados em pontos de 
controlo foram avaliados em termos de distribuição de dose através de filmes radiocrómicos, os 
quais foram posteriormente comparados com simulações. 
A quantidade de número de graus de liberdade pode ser aumentada através da rotação da mesa 
de tratamento e da gantry, o que permite a entrega de feixes de radiação a partir de qualquer 
ângulo. De maneira a perceber se a entrega de feixes a partir de diferentes direções pode 
melhorar as distribuições de dose e consequentemente os tratamentos aplicados, foram 
considerados 2 casos diferentes. Em ambos os casos as simulações foram baseadas em imagens 
de tomografia computorizada de feixe cónico. O primeiro caso dizia respeito a um rato com um 
glioblastoma multiforme e o segundo caso era baseado num rato com um tumor no pulmão. Os 
planos de tratamento foram avaliados com base em histogramas de volume-dose e nas 
respetivas métricas.  
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Nesta tese foram entregues pela primeira vez distribuições de dose complexas através de 
tratamentos baseados no movimento da mesa de tratamento e da gantry com recurso a pontos 
de controlo. Os resultados indicam um posicionamento preciso, confiável e reprodutível da mesa 
de tratamento durante todo o tratamento. Foi também provado que o irradiador consegue 
entregar tratamentos com um elevado número de pontos de controlo sem dificuldades. O estudo 
relativo às distribuições de dose mostrou uma elevada concordância entre os resultados obtidos 
com os filmes radiocrómicos e as respetivas simulações. 
Relativamente aos resultados acerca da necessidade de graus de liberdade em radioterapia com 
pequenos animais no caso do glioblastoma, estes indicam que tratamentos com feixes entregues 
de diferentes ângulos não melhoram a qualidade do tratamento em comparação com os 
tratamentos padrão feitos hoje em dia em radioterapia com pequenos animais. Em 
contrapartida, as simulações de diferentes planos de tratamento do caso referente ao tumor no 
pulmão mostraram que gaus de liberdade adicionais podem melhorar o tratamento desde que 
sejam utilizadas as configurações geométricas do feixe mais corretas. 
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ABSTRACT 
 
The aim of radiation therapy is to deliver a very high dose of radiation to a tumor, while trying to 
spare the surrounding normal tissues. Due to the need of dose distributions improvement, over 
the past two decades radiotherapy underwent through a series of developments where new 
complex radiotherapy techniques appeared. Meanwhile, these techniques are currently 
implemented in clinical practice without enough experimental validation. To face this problem, 
small animal irradiators can be a new platform for testing new treatment possibilities. There is a 
limitation in current small animal experiments where the treatments are mostly based on 
primitive irradiation techniques that are not representative of what really happens in clinical 
practice. To better mimic pre-clinical treatments to the ones used in clinical practice, more 
complex treatment plans with the possibility of delivering more complex and heterogeneous 
dose distributions are needed. In this way, the purpose of this study is to investigate the 
capability of the XRAD-225Cx microirradiator to deliver complex dose distributions through 
stage and gantry movements along with the need of additional degrees of freedom in pre-clinical 
treatments. 
Treatment plans were delivered using the pre-clinical radiotherapy platform Precision X-Ray 
XRAD-225Cx installed at MAASTRO Clinic (Maastricht, Netherlands) of which the absolute stage 
positioning was verified using an ultra sound sensor. More complex dose distributions can be 
achieved by using simultaneous table and gantry movement during irradiation and the 
feasibility of this technique was investigated through the use of control point (CP) based 
treatment plans consisting of high numbers of control points. The need for additional degrees of 
freedom in small animal radiotherapy was evaluated using cone-beam CT scans of 2 tumor 
bearing mice, a glioblastoma multiform (GBM) case and a lung tumor case. The tumors and the 
organs at risk (OAR) were delineated for both cases to simulate and evaluate different treatment 
plans in which different degrees of freedom were taken into account. To simulate all the 
treatments, a research version of the Monte Carlo based treatment planning system, SmART-
Plan was used.   
The results indicate an accurate, reliable and reproducible stage positioning during treatment 
delivery. The XRAD-225Cx proved to be able to deliver treatment plans with high number of 
control points and also proved to be able of delivering complex dose distributions through stage 
and gantry movement. Results from different GBM treatment plans indicate that treatments with 
additional degrees of freedom do not considerably improve treatment plan quality in 
comparison with standard treatments done nowadays in preclinal practice. In contrast, the 
simulations of lung tumor treatment plans showed that is possible that additional degrees of 
freedom with correct geometric beam configurations may improve the treatment.      
keywords: small animal radiotherapy, XRAD-SmART, Smart-Plan, dose distribution, degrees of 
freedom 
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1. INTRODUCTION 
 
1.1. General introduction and motivation 
Cancer is the main cause of death and morbidity in Europe after cardiovascular diseases (WHO, 
2015). According to the International Agency for Research on Cancer (IARC), in 2012, 14.1 million 
new cases of cancer appeared worldwide causing 8.2 million cancer related deaths (Stewart & 
Wild, 2014). The number of new cases of cancer is expected to increase to 24 million by 2035 
(WCRF International). Generally, cancer occurs when the normal cells in the body start growing in 
an uncontrolled way. There are many different types of cancer and they are typically named for 
the organ or the cell where the cancer begins. Some causes of cancer can be prevented but others, 
such as family history or aging cannot. In this way, early detection and better treatments are the 
best way to improve the cure.  
Radiotherapy plays an important role in cancer treatment since the discovery of X-Rays by 
Röntgen in 1895. Presently, almost 40% of all people with cancer have radiotherapy included on 
their treatment plan (CRUK, 2015). In radiotherapy, ionizing radiation is targeted to cancerous 
tissue in order to control tumor growth by causing cell death, which is possible due to the use of 
high energy beams of different types of energy like photons or charged particles. Ionizing 
radiation works by damaging the DNA of cancer cells leading to cellular death. Nearby healthy 
tissues also suffer temporary cell damage from radiation, but these cells are usually able to repair 
the DNA damage and continue growing normally (NIH, 2010). The treatment success is strongly 
correlated with the damage on cancer cells and the sparing of the healthy surrounding tissues. 
The amount of ionizing radiation delivered during a treatment is expressed as absorbed dose, 
measured in units of Gray (Gy), i.e. energy deposited per unit of mass (J.Kg-1). Radiotherapy can be 
performed by using external or internal radiation therapy. The most common type of radiation 
treatment is external radiotherapy and involves the delivery of radiation by a source that is 
located outside the patient body. In this case, the radiation is delivered by a linear accelerator 
which focuses high-energy radiation beams onto the area that requires treatment. In internal 
radiotherapy, also called brachytherapy, the radiation source is placed inside/near the tumor. 
Currently, radiotherapy can be used alone or in combination with chemotherapy. Furthermore, it 
can also be used before surgery to shrink a tumor, or after surgery to destroy tumor cells that may 
be left. 
Great technological advances have been taking place in radiation therapy over the couple last 
decades where new focused radiation techniques appeared, as 3-dimensional conformal 
radiotherapy (3D-CRT), intensity modulated radiation treatment (IMRT), image-guided radiation 
therapy (IGRT), stereotactic radiosurgery and dose painting. These techniques use advanced 
medical imaging techniques for targeting, use local beam intensity modulation and focused beams 
delivered from many different angles allowing the spare of the tumor adjacent healthy tissues. 
An increasing effort to improve the different radiotherapy techniques and to develop new ones in 
order to improve the efficiency of the radiation therapy treatments is evident. With the 
emergence of new techniques, radiobiological experiments and experimental validation are 
crucial before the implementation of these techniques in a clinical environment. Once it is really 
difficult to validate new techniques based on human trials due to practical and ethical concerns 
associated with human experiments, animal experiments appear as an essential approach in 
cancer research. This makes Small Animal Radiation Therapy an upcoming research field. More 
and more researchers and institutions recognize the importance of small animal radiation 
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therapy, which is shown by the acquisition of this kind of platforms from more than 60 
radiotherapy centers. 
The concept of radiotherapy, where cells are damaged by radiation, for small animals is 
equivalent to the human concept, whereby the radiation device for small animal radiotherapy is 
similar but of smaller dimensions. However, downscaling radiation therapy from a clinical setting 
to a smaller pre-clinical setting is not as simple as a geometric adjustment. For example in clinical 
practice, the treatment planning and the irradiation of the patient can take days or weeks. Though, 
in pre-clinical treatments the treatment process is performed while the animal is under 
anesthesia and the entire treatment has to be performed within 20 to 90 minutes in total (Figure 
1). Another major difference between clinical practice and small animal radiation treatments is 
the different size of the body of humans and small animals, as rats or mice, which leads to the 
need of radiation beams in the mm scale with a sub-millimeter precision. 
 
Figure 1 – Schematic overview of the different phases in precision small animal radiotherapy and the duration of each 
phase. Adapted from (Balvert, 2015). 
The recent development and commercialization of new small animal image-guided radiotherapy 
devices has made small animal radiotherapy experiments possible. These devices offer precise 
irradiation with Cone Beam Computed Tomography (CBCT) guidance and bioluminescence 
tomography for improved targeting. Several groups have recently started improving some 
existing systems and developing new research systems that allows precise irradiation of the 
tumors in small animals (Verhaegen et al., 2011). 
These new small animal irradiation platforms also offer treatment planning systems (TPS) with 
3D dose distribution and dose volume histograms (DVH) of the structures of interest. DVHs are 
usually used to evaluate the treatment plan. A DVH is a histogram relating the radiation dose 
delivered to a tissue volume. Treatment plans are created based on 3D images produced using 
Computed Tomography (CT) or Magnetic Resonance (MR) images. Assimilating the vast amount 
of information in a 3D radiation dose array is very difficult and DVH condenses this vast 
information into easily interpretable 2D graphs. There are two types of DVHs commonly used: 
differential and cumulative DVHs. The most common one is the cumulative dose-volume 
histogram (cDVH). This DVH displays the percentage number of voxels in a volume which receives 
at least a dose D. The cumulative DVH always begins at 100% (100% of the structures receive at 
least 0 dose). Thus for an ideal treatment plan, the DVH of the target volumes will have a 
rectangular, step-down function appearance and the DVH of the organs at risk will drop 
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immediately to zero (Figure 2). A drawback of the DVH methodology is that it offers no spatial 
information. 
 
Figure 2 - Cumulative Dose Volume Histogram representation for two different structures, target (e.g. tumor) and 
organ at risk, with a prescribed dose of 4Gy. The ideal and the real DVH are also represented for these two structures.  
 
1.2. Gamma Evaluation Method 
The gamma evaluation method was first introduced by Low et al. in 1998 and has been widely 
accepted for comparisons between two dose distributions, where one is defined as the reference 
information (Dr(r)) and the other as the comparison (Dc(r)). It is a dimensionless measure and is 
used in radiotherapy to evaluate the deviation between planned (calculated) and the actual 
(measured) dose distribution for a given treatment plan.  
The method uses the following two acceptance criteria: distance to agreement (ΔdM) and dose 
difference (ΔDM). As a final result, a dose difference distribution is calculated and the regions 
where the simulated dose distributions disagree with the measurements are displayed. The 
acceptance criteria is defined by an ellipsoid, in which the boundary represents the acceptance 
criterion. The equation of the ellipse can be written as: 
                                                                        𝑙 = √
∆𝑟2
∆𝑑𝑀
2 +
∆𝐷2
∆𝐷𝑀
2                                                                                [1] 
where rr is the reference point, Dr is the receiving dose at rr, Δr=|rr-rc| represents the distance 
between the reference and the compared point and ΔD= DC(rc)- Dr(rr) represents the dose 
difference at the position rc relative to the reference dose Dr at rr. Figure 3 shows a schematic 
representation of the gamma analysis method for two dimensional dose distribution evaluations. 
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Figure 3 - Geometric representation of dose distribution evaluation criteria using the combined ellipsoidal dose-difference 
and distance-to-agreement tests. 
A quantitative measure of the method is determined by the gamma value,  𝛾, which represents the 
minimum distance between the reference point and the compared distribution: 
                                                                       𝛾(𝑟𝑟) = 𝑚𝑖𝑛{Γ(𝑟𝑐 , 𝐷𝑐)}∀𝑟𝑐                                                  [2]                                                  
                                                                    Γ(𝑟𝑐 , 𝐷𝑐) = √
∆𝑟2
∆𝑑𝑀
2 +
∆𝐷2
∆𝐷𝑀
2  ≤ 1                                              [3] 
For the dose distribution to match the reference point, it needs to contain at least one point 
(𝑟𝑐 , 𝐷𝑐) lying within the ellipsoid of acceptance. 
The pass-fail criteria leads to: 
|𝛾| ≤1, the points meet the acceptance criteria and the points are considered to pass the 
gamma analyses, 
|𝛾| >1, the points do not meet the acceptance criteria and the points are considered to fail 
the gamma analyses. 
The points failing the criteria can be distinguished as points with a higher or lower dose in 
comparison to the reference point. Positive gamma values represent an increase in dose 
(hotspots) and negative gamma values represent a decrease in dose (cold spots).  
An example of a gamma analysis is presented in figure 4. The color map for the gamma analyses as 
two transitions at 𝛾 = 1 and 𝛾 = -1. The points in the green region are considered to pass the 
gamma criteria, the points in the red (hot spot) and blue (cold spot) regions are considered not to 
pass the gamma criteria. 
 
Figure 4 – Gamma analyses example. 
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1.3. Purpose of the project  
Over the past two decades, due to the need of improving dose distribution, radiotherapy 
underwent through a series of developments where new complex radiotherapy techniques 
appeared. Meanwhile, these techniques are already implemented in clinical practice without 
enough experimental validation or strong evidences of its superiority over other techniques. Data 
based on clinical human trials is difficult to obtain, which makes small animals trials a viable 
alternative. Although small animal experiments are the best approach, the treatments are mostly 
based on primitive irradiation techniques. For example the standard treatment utilized to treat 
small animals uses static single beams often involving partial-body irradiation, which is not 
representative of what really happens in clinical practice. These differences between the current 
treatment applied to small animals and the treatments applied in clinical practice present 
disadvantages for translational knowledge. To better mimic pre-clinical treatments to the ones 
used in clinical practice more complex treatment plans with more complex or heterogeneous dose 
distributions are needed. In this way the first aim of this project is to investigate the feasibility of 
the in house small animal radiation treatment platform (XRAD-225Cx) of delivering complex dose 
distributions through stage and gantry movement. Treatments based on full stage and gantry 
rotation allow the delivery of beams from any desired direction and angle which brings a new set 
of treatment possibilities. Moreover, this project will also investigate if the addition of different 
degrees of freedom in small animal radiotherapy may lead to improved dose distributions in 
comparison with the current standard animal treatment. 
 
1.4. SmART Group 
The SmART group is a group integrated in the Department of Radiation Oncology at Maastro Clinic 
(Maastricht Radiation Oncology) based in Maastricht, Netherlands. Maastro is an institute that 
investigates the field of radiation oncology with interdisciplinary clinical, translational and 
research in physics and biology. The clinic works closely with Maastricht University (UM). The 
SmART group is focused on the improvement of the acquired small animal research platform 
(XRAD-225Cx) and development of new techniques which allows increasingly better pre-clinical 
investigation, enabling the performance of in vivo radiobiological studies in a similar manner to 
clinical practice. The SmART group works in collaboration with many institutes and groups, 
particularly with a group named Maastro Lab that investigates the basic mechanism of treatment 
failure in cancer and tries to apply this knowledge to improve outcome for cancer patients.    
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2. BACKGROUND 
In the past few years new irradiation techniques of radiotherapy have been investigated, 
developed and implemented in clinical practice, which brought an unprecedented level of 
sophistication in cancer treatment. With the increasing complexity of novel radiotherapy 
techniques and the need of validation of those techniques, precise small animal irradiators 
became important to investigate them. In addition, these techniques also allow in vivo 
radiotherapy drugs experiments on small animals (Butterworth et al., 2014). Many of these novel 
techniques haven’t been properly tested or validated with animal experimental data. The ones 
tested in animals are mostly based on primitive irradiation techniques only able to administer 
large radiation fields where a considerable volume of healthy tissues surrounding the tumor are 
also irradiated. Consequently, these treatments are not representative of what really happens in 
clinical practice. In this way these techniques have been introduced without solid proof from lab 
animal experiments to demonstrate their long-term benefit and superiority over less conformal 
irradiation techniques.   
For scientist to understand the mechanism and pathways of cancer and its evolution and 
spreading over the body and to discover new ways to diagnose and treat cancer it is necessary to 
carry out experiments on live animals. During studies of radiation effects on tumors and 
surrounding cells in small animals, there is an increasing need for the development of small 
animal irradiation devices, which can be capable of targeting and delivering beams in a precise 
way, especially when investigations include the synergistic effects of different cancer treatments. 
Due to the advances in technology it is now possible to use radiotherapy approaches for research 
in small animals, like rats, mice and rabbits. Pre-clinical cancer studies (over 95% of which are 
conducted on mice) are essential to extend the knowledge and understanding of the mechanisms 
responsible for cancer and to identify, for example, new targets and biomarkers (Workman et al., 
2010). Animal studies fall into two broad categories: those using tumor cell transplantation, and 
those in which tumors arise or are induced in the host. The choice of the animal tumor model 
depends on the scientific question being investigated. Connecting the existing knowledge of small 
animal tumor models with the improved small animal radiotherapy platforms the effects of 
radiotherapy alone or in combination with chemotherapy and/or surgery can be studied with 
small animals. 
Although radiotherapy in small animals may be similar to the modern human radiotherapy 
process, the size of small animals when compared with humans is largely different. Due to the 
small size of the animals used for experimental research, their tumors also have a small size. For 
example a rat brain has an average size between 1.0 cm and 1.5 cm long (Beekman & Vastenhouw, 
2004), whereby a brain tumor is even smaller with dimensions in the order of a few millimeters. 
To have a higher level of treatment accuracy with precise targeting and delivery of high doses a 
3D volume sub-millimeter precision is required (Verhaegen et al., 2011). Another major 
difference is related with the beam energy. In small animal radiotherapy it is necessary to use 
kilovoltage energy beams instead of megavoltage photon beams as used in clinical practice due to 
the extent of the dose build up region, which may go beyond the size of the small animal. In this 
way to avoid extensive disequilibrium dose regions, kV photons between 100 kVp and 300 kVp 
generated by an X-Ray device are required.  
Inherently associated with the accuracy and precision of the treatment in small animals is the 
image system detection, acquisition and processing. The preferred image modality used in small 
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animal research platforms is cone beam CT imaging for detection and localization of different 
structures and treatment planning. The X-Ray detector should have a high temporal resolution 
and a frame rate of 50 ms for respiratory gating. Due to the size of the animals, micro-CT scanners 
should acquire voxel volumes with 100 µm3. 
2.1. Small Animal radiation therapy research platforms 
Pre-clinical animal experiments have been an essential tool in evaluating the effectiveness of 
anticancer therapies, studying the underlying mechanisms of disease response, and providing 
evidence of safety for new drugs and devices. In radiotherapy and radiobiology research, pre-
clinical experiments have been used to investigate the response of tumor or normal tissue to 
radiation exposure, usually with small animals such as mice and rats (Jeong et al., 2015). To 
overcome these problems, small animal radiotherapy research platforms have been developed by 
several institutions. There have been numerous publications related to the development of 
research systems capable of precise irradiation of structures in small animals. Groups from Johns 
Hopkins University, Princess Margaret Hospital, Washington University, Stanford University and 
University of Texas Southwestern have either commenced modifications on existing technologies 
or have developed new ones using their own resources. Among them, there are two relatively 
mature systems developed independently from Princess Margaret Hospital and Johns Hopkins 
University.  
2.1.1. XRAD-SmART 
The XRAD-225Cx device was developed at the Princess Margaret Hospital (Canada) in 
collaboration with the company that commercializes it, Precision X-Ray Inc., and provides in the 
same platform a high resolution CBCT imaging system and an X-Ray source (5-225KeV). They are 
both mounted on opposite sides of a C-arm, which rotates 360ᴼ for imaging and irradiation, as 
shown in Figure 5 b) (Verhaegen et al., 2011). In this platform images are acquired in a similar 
way as they are obtained in clinical practice in which the specimen is stationary and the source 
and detector rotate around the object. The XRAD-225Cx is enclosed in a cabinet (Figure 5 a)) with 
two walls of steal and one of lead in-between. It has an inherent collimation and filtration system, 
manually interchangeable in order to specify the beam size and to deliver the appropriate 
spectrum for each treatment, respectively. The uncollimated field is a 10 cm x 10 cm square and 
the available collimators allow a beam size range from 0.1 cm in diameter to 10 cm x 10 cm 
square. There are two filters presently available, a 2.8 mm aluminum filter and a 0.3 mm copper 
filter. The system can deliver dose rates of approximately 4Gy/min. To acquire the images, the 
XRAD-225Cx device has a flat panel detector, consisting of amorphous silicon elements, that is 
able to image a 10 x10 x 10 cm3 volume with a maximum resolution of 0.1 mm3. The XRAD-225Cx 
also has an animal stage capable of precise motion in the 3 cardinal directions. The stage has an 
automated stage correction that corrects for slight motions of the X-Ray tube with respect to the 
isocenter and the imaging panel during irradiation, which permits a great stability and 
reproducibility of irradiation. For animal monitoring, 3 webcams are attached in different places 
inside the cabinet. 
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Figure 5 – XRAD-225Cx device developed at the Princess Margaret Hospital. (a) Cabinet that encloses the XRAD-225Cx 
device. (b) XRAD-225Cx device and its components. 
2.1.2. SARRP research platform 
The small animal radiation research platform (SARRP) (Wong et al. 2008) developed at Johns 
Hopkins University and marketed by Xstrahl (Camberley, United Kingdom) integrates a high 
accuracy cone beam CT imaging system and a high dose delivery X-Ray source in a single 
platform. The SARRP system and its components are shown in Figure 6 a). The platform consists 
of a dual-focus constant voltage X-Ray source operating up to 225 kVp, a flat panel detector for 
target localization, mounted on a gantry with a nominal source-to-isocenter (SID) distance of 35 
cm and a robotic stage. This system, like the previous one, can deliver dose rates of approximately 
4Gy/min. The gantry can be rotated manually and the rotation is limited from the top to 120° with 
increments of 15°. To position the animal, computer controlled robotic translation and rotation 
stages are used. The robotic stage offers 4 degrees of freedom in x and y (cross-table), z (vertical 
movement) and θ (rotating table). The accuracy of motion in the xy direction and in the z 
direction is 65 μm and 125 μm, respectively. The accuracy of rotation is 0.05° (Matinfar et al. 
2009). Compared with the platforms used in clinical practice, there is an outstanding difference 
between the SARRP gantry and the one used in clinical practice. In the SARRP system in order to 
acquire a CT image or to deliver arc beams, instead of rotating the gantry, the stage rotates a full 
360° with the gantry at 90°, as shown in Figure 6 b). The SARRP system has an open field size of 
20 × 20 cm used for imaging. For irradiation purposes the field can be downsized to a diameter of 
0.5 mm due to different manually interchangeable collimators. The SARRP imaging system uses a 
flat panel amorphous silicon detector with a dimension of 21 cm x 21 cm, which is in the opposite 
position of the X-Ray source. There are two options for the flat panel detector: 512 × 512 pixel or 
1024 × 1024 pixel, providing resolutions of 400 μm and 200 μm, respectively. 
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Figure 6 - (a) SARRP system and the components installed at John Hopkins University with conformal irradiation and 
cone beam CT guidance capabilities, adapted from (Marchant & Moore, 2014). (b) Representation of the irradiation 
procedure, where the animal is placed in a rotatable stage between the X-Ray tube source and the detector.  
2.1.3. SAIGRT system 
The small animal image-guided radiation therapy (SAIGRT) is a non-profit academic small animal 
radiation therapy research platform developed at the Faculty of Medicine and University Hospital 
Carl Gustav Carus (Dresden, Germany) in collaboration with different institutes. The SAIGRT 
platform allows for highly precise and accurate conformal irradiation and X-Ray imaging of small 
animals. It offers a technology comparable to modern human radiation therapy with photons. The 
platform integrates a 225 kV X-Ray tube used for both imaging and irradiation purposes (Figure 
7). By changing the X-Ray source parameters and filtration, the SAIGRT system can provide a wide 
range of dose rates (<1 mGy.min−1 to several Gy.min−1) and different photon energy spectra. 
Furthermore, a digital flat panel X-Ray detector with an active area of 12.32 cm × 11.20 cm and a 
pixel size of 0.01 cm × 0.01 cm is integrated to perform conventional radiography (CR) and cone 
beam CT for both treatment planning and animal position verification. The SAIGRT includes an 
inherent beam collimation system enabling treatments of target volumes with a diameter 
between 1 and 20 mm allowing for simple, non-conformal (e.g. rectangular or circular) field 
shapes. Small animal experiments are carried out at the gantry module, which comprises of a 3D 
computerized stage unit made from 2 mm thick carbon fiber and a 360° rotating arm. The rotating 
arm carries the X-Ray tube, the system of flat aperture collimators for field formation and the 
digital flat-panel detector. The device is enclosed by a sandwich aluminium-lead plates with 10 
mm thick lead for radiation protection. The system is intended to examine a single anaesthetized 
small animal.  
 
Figure 7 – a) Detailed view of the gantry SAIGRT module. Main components are: (1) rotating arm, (1a) X-Ray tube, (1b) 
primary collimator and filter slot, (1c) secondary collimator, (1d) flat-panel detector, (2) stationary unit, (2a) animal bed, (2b) 
a) b
) 
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animal stage positioner. b) Simplified scheme of the SAIGRT movement components: rotating arm and 3-D computerized 
animal bed. 
2.1.4. Small animal irradiator based on GE eXplore RS120 microCT scanner 
Besides these previous mature small animal research platforms, there are other platforms under 
investigation and development. A new small animal irradiator platform was developed by a group 
at Stanford University (Zhou et al. 2010) based on a GE eXplore RS 120 micro CT scanner. A 2D 
translation stage and a variable aperture collimator were added to the initial system (Figure 8). 
The system operates at a tube current between 70 and 120 kVp with a maximum current of 50 
mA. The X-Ray tube and the detector panel are placed in opposite sides of the gantry. The 
platform has a stage system that allows the stage to move along the CT axial direction to carry the 
animal into and out (z-axis in the CT coordinate system) of the CT scanner for imaging. In order to 
move the animal in the two other cardinal directions a 2D stage was added (x, left or right and y, 
up and down). The stage can move 10.2 cm in the z direction, 5.08 cm in the x direction and 2.0 cm 
in the y direction. A collimation system consisting of two stages, each of them with an adjustable 
hexagonal iris capable of producing a hexagonal field size between 0.1 cm and 6.0 cm, was added 
and it is represented in Figure 8 a). The two irises are offset by 30◦ so that when the openings of 
the two stages are properly adjusted to the same size, a dodecagonal beam profile is formed. This 
system is capable of deliver dose rates of approximately 2 Gy/min.  
 
Figure 8 – Stanford University micro-CT scanner for irradiation of small animals. (a) Representation of the bottom iris 
collimator formed by six sliding blocks mounted on linear tracks. (b) From bottom to top: X-Ray tube, collimator in its 
holder, plexi glass CT bore that holds a translation stage and the animal and CT detector. Retrieved from (Zhou et al. 
2010). 
 
2.1.5. MicroRT—Small animal conformal irradiator 
A more basic small animal irradiator was developed at Washington University and this system is 
drastically different from most X-Ray tube based systems (Stojadinovic et al. 2008) since it utilizes 
a high dose rate Ir-192 brachytherapy source with a half-life of 74 days and an average gamma-
Ray energy of 309 kV as source. As shown in figure 9, the animal can be placed on a three-axis 
motor stage to move it and the stage is shielded by an aluminum collimator assembly. The 
aluminum collimator assembly has dimensions of 30.48 cm long, 0.95 cm thick and 15.24 cm 
outer diameter that holds custom-built tungsten collimators. The stationary beams can be 
delivered from four directions: 0°, 90°, 180°, and 270°. There are four openings equally spaced on 
the aluminum collimator assembly that can fit different tungsten collimators providing field sizes 
of 5 to 15 mm. Once the device has no imaging capabilities, the animal positioning is based on 
external fiducial markers.  
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Figure 9 – Small animal irradiator developed at Washington University. (a) Collimator assembly which can 
accommodate 192Ir source. (b) computer controlled animal stage in relation to the collimator assembly. 
With the exception of the last system, all the previous ones presented here have an integrated 
anesthetic system based on inhaled anesthesia gas. In the last system the anesthesia is 
administered by injection. 
 
2.2. Treatment planning systems (TPS) for small animals   
While the development of micro-irradiator devices had improved the image quality and the 
irradiation of small structures, a proper treatment planning system (TPS) capable of calculating 
dose distributions correctly in small structures is needed. Treatment planning is one of the most 
time consuming phases of a common treatment workflow of small animals treatment as can be 
seen on Figure 1. A TPS capable of calculating dose distributions is very important not only 
because it gives information about the dose distribution within the target but also because it gives 
information about the amount of radiation delivered to regions outside the target. This motivated 
the development of treatment planning systems that enables the researcher to specify a treatment 
plan, consisting of one or more beams applied to one or more targets. These treatment planning 
systems compute the dose distribution and allow the visualization of the resulting dose volume 
distribution on the structures. Presently, there are two main treatment planning systems being 
used for small animal irradiations.  
2.2.1. XRAD SmART-Plan TPS 
Recently a TPS called Small Animal Radiation Therapy Plan, (SmART-Plan) was developed by the 
department of radiotherapy of MAASTRO Clinic (Maastricht, Netherlands) (van Hoof et al., 2013). 
SmART-Plan was developed in MATLAB, is executed on a Linux-based platform and is based on a 
robust Monte-Carlo algorithm. The X-Ray device and its collimators are modeled by a photon 
source from a previous MC simulation (Granton et al., 2012). SmART-Plan allows the user to 
import the 3D structure of the specimen into SmART-Plan and then the different structures are 
assigned to different materials according to the Hounsfield Units (HU). The conversion of HU to 
material type and density is based on a calibration curve. The HU to density calibration curve was 
constructed based on a phantom with known tissue substitute inserts. Based on a voxel phantom 
derived from the CBCT scan different structures can be delineated (Figure 10) and targets can be 
countered. SmART-Plan is capable of simulate static and dynamic beams from a 360ᴼ arc 
revolution. As a result of the simulation, SmART-Plan displays 3D dose distributions and dose 
volume histograms (DVH) of the specified structures. 3D dose distribution and DVH can be 
optimized by manually adjust the beam weights. SmART-Plan was validated by comparing the 
calculated absolute depth dose curves and dose distributions in various homogeneous and 
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heterogeneous phantoms against the measurements obtained with radiochromic film for 1, 5 and 
15 mm collimator. 
More recently, a group from the department of Econometrics and Operations Research (Tilburg 
University, Netherlands) in collaboration with the department of Radiation Oncology of Maastro 
Clinic (Maastricht, Netherlands) developed a framework for inverse planning of beam-on-times 
for 3D small animal radiotherapy (Balvert et al., 2015). Once the degrees of freedom are 
increasing the manual creation of beam configurations and dose optimization becomes more 
complicated and the treatment plan becomes more dependent on the user skills, in this way an 
inverse treatment planning appears as an important and easier solution for dose optimization. 
Here, they presented a mathematical model that automatically optimizes beam-on-times. This 
software is capable of calculating different beam weights based on the specified beams by the user 
and through an interactive procedure various optimal solutions are generated. In the end, the user 
can choose the optimal solution. SmART-Plan was used to create beam configurations and 
perform dose calculations.  
 
Figure 10 – SmART-Plan interface. Countering step where the structures of interest are defined and delineated. 
2.2.2. SARRP MuriPlan TPS 
A group from Johns Hopkins University (Baltimore, USA) developed a TPS for the SARRP platform 
based on the 3D Slicer package (Cho & Kazanzides, 2012), which is an open source application for 
medical image visualization and analysis (The Slicer Community, 2015). The dose computation 
was implemented on a graphical processing unit (GPU) to achieve faster processing and it uses the 
superposition-convolution method to compute dose, rather than Monte Carlo simulation. The TPS 
module shown in figure 11 a) consists of four stages: Experiment Info, where the images of the 
animal are uploaded; Target Selection, Treatment Planning (Figure 11 b)), and Treatment Plan 
Execution. Users are allowed to specify a prescribed dose for each target and create a plan 
consisting of multiple beam and/or beam arcs. For each entry, the user can specify the isocenter, 
collimator type, couch and gantry angles, and beam weights. Once a valid plan is created, it can be 
sent to the dose engine in the SARRP software for execution. The SARRP software receives the 
plan, and calls the GPU engine to compute a separate dose volume for each plan entry, and then 
returns the weighted sum of those volumes (i.e., based on the specified beam weights), as well as 
the exposure time for each plan entry. The SARRP-TPS was validated with 5 different phantom 
setups (Cho & Kazanzides, 2012). For each setup, a stack of 4 materials with different densities 
were used. 5 EBT2 films were placed between 5 mm heterogeneous phantom slices.  
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Figure 11 - SARRP treatment planning system interface. (a) 4 steps of SARRP TPS. (b)  SARRP TPS treatment planning 
step, for a treatmnt with 1 isocenter and 3 beams. 
2.3. Other developments and studies in small animal radiation therapy 
Pre-clinical in vivo studies using small animals are crucial for translational cancer research to 
develop and optimize therapeutic options of radiotherapy and combined systemic treatment, to 
examine their efficacy and to investigate side effects. Local irradiation requires reproducible 
animal positioning, image-guided target localization and accurate beam application to avoid 
serious side effects when therapeutically relevant doses are being administered using clinically 
acceptable fractionation schemes. In addition, there is the inherent motion within the animal’s 
body caused by breathing, heart beat or bowel gas (Bartling et al 2008, Kuntz et al 2010, 
Rubinstein et al 2013) that needs to be taken into account. Despite all the developments made in 
small animal radiotherapy, research is continuously being made to overcome different technical 
issues in order to allow more complete and accurate studies.   
In pre-clinical radiotherapy when small animals are treated multiple times, reproducibility in 
inter-fractional treatments is required. To face this problem, a group from Texas University 
developed 3D-printed immobilization device for mice that allows quick and reproducible small-
animal setup (McCarroll et al., 2015). The printed design significantly reduced setup variation, 
with average reductions in rotational displacement of 76% ± 3% and a translational displacement 
within the printed immobilizer less than 1.5 ± 0.3 mm. 
Gating is necessary in thoracic imaging to prevent a loss of image quality and to acquire 4D data 
sets. During image acquisition there is a loss in image quality because the acquisition of CT image 
data takes much longer than the duration of a respiratory and/or a cardiac phase. Image quality is 
then restricted by the motion of the heart and lung (Bartling et al., 2010). Gating in small-animal 
imaging requires the acquisition of a gating signal during scanning, which can be done 
extrinsically or intrinsically from the projection data itself. In extrinsic gating, a motion signal is 
acquired through an external hardware system for example a camera or a laser system. In this 
way, the gating signal is used retrospectively during CT reconstruction, or prospectively to trigger 
parts of the scan. A wide variety of gating methods in small-animal, CT exist and new ones are 
being developed. The CT scanner type, the scanned animal, and the diagnostic question all have to 
be taken into account in order to implement gating successfully. The scan protocols, gating 
parameters and gating algorithms have to be carefully selected and optimized. 
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In order to deliver treatments based on dose painting, recently a group from Johns Hopkins 
University (Baltimore, USA) proposed a method to decompose  a 2D target in a variable number of 
rectangles of variable sizes that can be shaped with different collimators (Cho et al., 2014). This 
method consists of several distinct steps: segmentation, simplification, and decomposition, shown 
in figure 12, and was implemented on the SARRP treatment planning system. The segmentation 
step converts the raw image to a 2D label map (i.e., target area) by using the segmentation tool 
available in 3D Slicer. In the simplification step the label map is approximated to a rectilinear 
polygon. Finally, in the decomposition step, the rectilinear polygon is decomposed into the 
minimum number of rectangles possible. Their simulations showed that higher doses occurs 
primarily at the boundaries between the rectangles, whereby more research needs to be done to 
investigate this topic. Moreover this prove of concept still needs validation for example with 
experiments with radiochromic films.  
 
Figure 12 – (a) to (d) Different steps of the method developed by a group of Johns Hopkins University to decompose a 
2D target in a variable number of rectangles of variable sizes. (e)  2D Dose distribution of the target divided in different 
rectangles of different sizes computed by SARRP TPS with a beam time of one minute for each rectangular region. 
In 2014 a group from the Department of Radiation Oncology at Maastro quantified local changes 
in mice’s lung density by using an image guided small animal irradiator (SmART) for precise 
irradiation (Granton et al., 2014). In this study they divided 76 adult male mice into 6 groups: a 
control group (0 Gy) and groups irradiated with single fractions of 4, 8, 12, 16, or 20 Gy using 5 
mm circular parallel-opposed beams, targeting the upper right lung. After irradiation, all mice 
were imaged at regular intervals over 39 weeks. They discovered that mice irradiated with 
prescribed doses greater than 10 Gy exhibited a steady increase in lung density most pronounced 
for the 20Gy group, having a maximum difference of 120 HU at the 39th week endpoint compared 
to the control group. They were also able to show that partial lung irradiation can induce 
symptoms characteristic of RILF (radiation-induced lung fibrosis) that are discernible as early as 
10 weeks post irradiation compared to the nonirradiated group. The data comparison between 
their results and results from previous pre-clinical studies where large radiation fields, often 
covering the whole thorax with limited knowledge of where radiation was delivered, were used 
showed that for the same prescribed dose the severity of RILF in partial lung irradiation in mice 
can be reduced when a small animal irradiator allowing precise irradiation and the delivery of 
smaller beams is used. 
A study performed by a multidisciplinary team of Ghent University Hospital (Belgium) validated 
magnetic resonance imaging (MRI) as a possible choice as image modality for guided micro-
irradiation for the F98 glioblastoma rat model using SARRP (Bolcaen et al., 2014). MRI images 
were used to define the target and the CBCT was used to calculate the dose plan. In the study 10 
rats were inoculated with F98 tumor cells in the right frontal hemisphere and then were treated 
by combining radiotherapy with temozolomide (oral chemotherapy drug). Four different 
radiotherapy treatment protocols were applied, all of them with a delivered dose of 20 Gy to the 
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tumor volume. In the first treatment only the on-board CT for imaging was used for delineation 
and dose planning. In this treatment a single static beam was delivered with a width of 10 mm, 
once the tumor was not visible. For the other 3 remaining treatments an MR image was used to 
delineate the tumor, which allowed the use of a 3 mm x 3 mm collimator. With the tumor 
delineated dose plans for a single beam, a single arc and 3 non-coplanar arcs were delineated. The 
comparison of the different treatment plans showed that the homogeneity of the dose distribution 
increases from a single static beam, a single beam arc and three non-co planar arc beams. The 
results also showed that the most important difference between using a single CT-guided beam 
and a MRI-guided beam is the low dose delivered to the normal brain tissue when MR images are 
used for delineation, with the three non-coplanar arcs beams MRI-guided treatment being the one 
that delivers less dose to the normal brain. Using the approach with the SARRP and concomitant 
TMZ, tumor growth was stable until 9 days post-irradiation, while tumors in the control group 
showed rapid proliferation. 
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3. MATERIALS AND METHODS 
 
3.1. SmART X-Radiation platform 
The small animal research platform used at MAASTRO Clinic is the XRAD-225Cx device (Figure 
13). The specifications of the irradiation, imaging and hardware of SmART platform are presented 
on Table 1. 
Table 1 – Overview of the properties of the XRAD-225Cxplatform according to the manufacturer. Adapted from (van 
Hoof, 2012). 
Geometrical setup 
Source to detector distance (SDD) 645 mm 
Source to isocenter distance (SID) 307 mm 
Irradiation 
Energy 5 - 255 kVp 
Dose rate up to 4 Gy/min 
Beam Orientation fixed and/or dynamic 0 to 360 degrees 
Interchangeable filtration 2.0 mm Al and 0.32 mm Cu 
X-Ray Power Supply 
Max output voltage 225 kV 
Max output current 45 mA 
Max Output Power 45 kW 
X-Ray tube (Unipolar Metal Ceramic Tube) 
Nominal Operating Voltage 225 Kv 
Inherent Filtration 0.8mm Be 
Target Material Tungsten 
Collimators Circular Rectangular 
beam size (mm) 1.0 10 x 10 
 
2.5 20 x 20 
 
5.0 30 x 30 
 
10 40 x 40 
 
15 10 x 30 
 
25 30 x 40 
Animal Stage 
Load capacity 4.5 kg 
Positional accuracy 82 µm 
Stage speed up to 36mm/s 
Maximum Travel Lateral (x) 184.47 mm 
 
Longitudinal (z) 129.71 mm 
 
Vertical (y) 180.92 mm 
Gantry 
Gantry speed 0.01 to 3.0 RPM 
Positioning accuracy < 6 arc per minute 
Imaging detector (silicon flat panel) 
Active pixels 1024 x 1024 
Pixel pitch 200 μm 
Total Area 20 cm x 20 cm 
Maximum frame rate 30 fps 
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Figure 13 - XRAD-225Cx platform installed at MAASTRO Clinic and its components. The X-Ray tube (bottom, white) is 
supported by the C-arm (orange). On the top of the C-arm is visible the cone beam CT imaging panel (dark gray). In 
between the CT imaging panel and the X-Ray source is located the 3D computer-controlled animal stage. 
Pilot workstation and Pilot treatment protocol   
To be able to access the CBCT acquired images, deliver the treatment plan, guide the targeting 
system and control system calibrations a user interface is needed. In the case of the XRAD-225Cx 
the software responsible for this, is a control software called Pilot, which was developed at 
Princess Margaret Hospital (Canada). Both of them are provided by the small animal facility at 
MAASTRO Clinic. Through this main user interface, the user has access to the CBCT acquired 
images of the specimen, which allows him to choose and fix the target isocenter that can be 
selected by moving the stage to the right position (Figure 14). Scans and treatments are organized 
in a searchable database by researcher and study. Since a high resolution CBCT scan of a large 
volume is time and memory consuming, firstly a CBCT with low resolution is acquired for gross 
overview of the specimen and afterwards a high resolution CBCT scan is done in a smaller 
selected region of interest. The treatment plan is based on the acquired CBCT data and for each 
treatment a protocol is generated as a text file. Pilot receives the treatment protocol and XRAD-
225Cx executes it, delivering the proper treatment by irradiating the target as specified in the text 
file.  
A treatment protocol is a structured text file that describes a sequence of steps, motions, 
irradiations, beam angles and other variables needed to deliver a proper treatment. A treatment 
protocol consists of a number of beams and each one of them is divided in control points (CPs). A 
CP is the representation of the machine state in a specific moment of time. For each CP can be 
specified the stage position, the beam angle, the gantry rotation direction and respective delivered 
dose. The dose is delivered in a segment between CPs and is measured as “seconds of beam-on-
time”. Thus the dose is measured according to the time that the beam is on. An example of a 
treatment plan protocol can be found in appendix A. 
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Figure 14 – Pilot interface displaying a low resolution CBCT data in the axial, sagittal and coronal planes. It can be seen 
in orange the selected region to acquire the high resolution CBCT scan. 
 
3.2. Treatment Planning System 
SmART-Plan is the TPS associated to the XRAD-225Cx platform. It is divided in six different 
sections (Figure 15). In the first section, Start case, the CBCT data is imported as a DICOM file. In 
the CT2MD section the different structures are assigned to the corresponding material. In the 
Contouring section the user can delineate and specify the important structures to be irradiated or 
to be avoided. To calculate the dose distribution the user needs not only to add a target and the 
prescribed dose, but also to specify the number of beams and beam angles used (Beams section). 
After the user specifies the number of generated particles per beam, the treatment is simulated in 
the Calculation section. When the simulation is over, SmART-Plan displays a 3D dose volume 
distribution and the DVH for the specified structures in the Visualization section as it can be seen 
in Figure 15. In this section the user can also change the beam weights and new dose volume 
distributions and DVH are generated. 
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Figure 15 - SmART-Plan interface. Visualization section where the 3 different views (axial, sagittal and coronal) of dose 
distribution and DVH are displayed for two structures, a mouse tumor (target) and the brain (minus target). 
 
3.3. EBT3 films 
 A verification process to evaluate real delivered doses is needed and radiochromic films appeared 
as a relevant tool to assess dose distributions. In particular, Radiochromic EBT3 film (Ashland Inc) 
was accepted by the scientific community as a reference two-dimensional detector. The EBT3 film 
is made by laminating an active layer with a yellow marker dye between two polyester layers with 
equal thicknesses (Figure 16 a)).  Radiochromic EBT3 film changes its color when exposed to 
radiation and the amount of color change is dependent on the dose it receives (Figure 16 b)). 
When the film is irradiated, the ionizing radiation initiates a polymerization process in the active 
layer that changes the optical absorbance. By digitizing the film using a document scanner, it 
becomes possible to access the optical density with respect to the dose. To convert the response 
of the radiochromic film (change in optical density) into absolute dose, a calibration curve is 
needed. EBT3 film is an important tool to access the dose due to its high spatial resolution, 
energy-independent dose response from the kV to the MV range, as well as its near-tissue 
equivalence.  
 
Figure 16 – (a) Radiochromic EBT3 film structure with different layers of different materials and different thicknesses. 
(b) Color change of a piece of a Radiochromic EBT3 film after irradiation. 
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3.4. Stage positioning validation 
To be able to deliver heterogeneous dose distributions by using stage motion during irradiation it 
is extremely important to assess the performance, the accuracy and the stability of the animal 
stage. To measure the animal stage movement, an ultra-sound (US) system was used (BALLUFF, 
BUS RO04K) (Figure 17).  The specifications of the US sensor are presented in Table 2. The time 
resolution of the US sensor was set to 12 ms for all the measurements. 
Table 2 – Specification of the Ultra Sound sensor to evaluate the SmART animal stage. 
Blinding zone  0 – 20 mm 
Operating scanning range 20 – 150 mm 
Limiting scanning range 250 mm 
Resolution 0.056 mm 
Response time 24 ms 
                                              
 
 
Figure 17 - Ultra-sound system used to evaluate the animal stage of the XRAD-225Cx (Precision X-Ray, CT, North 
Branford). 
3.4.1. Calibration and validation of the US sensor 
As a first step and before evaluating the stage positioning, a validation of the US system was 
needed.  To validate it, a dynamic thorax phantom “CIRS” (Universal Medical, model #008A) was 
used (Figure 18).  
The CIRS phantom is a precision instrument used to investigate the impact of tumor motion inside 
the lung and patient positioning errors in radiation therapy. The phantom body represents an 
average human thorax in shape, proportion and composition. A major component of the dynamic 
system is the precision motion actuator. The three-dimensional motion to the tumor in the 
phantom body is achieved by the actuator which applies synchronized linear and rotational 
motion to a moving rod. Sinusoidal and other complex motions can be achieved with sub-
millimeter accuracy and reproducibility. The CIRS phantom allows simulations of sinusoidal 
movements, for which the amplitude and period can be specified. With the amplitude and period 
defined, the periodic movement was measured with the US system and was compared to the 
sinusoidal movement of the CIRS phantom. As the output of the US sensor is an analog signal, an 
ADC (Analog to Digital Convertor) is needed to convert the analog signal (voltage) to a digital 
number. To smooth the ADC signal (digitalized value of voltage) an average filter was used. The 
average filter used was based on a filter, where the ADC value that is being filtered is replaced by 
the mean ADC value of the four previous ADC values including itself. Once the output of the US 
system is in ADC values, a calibration is needed to convert the ADC values to distance. To calibrate 
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the US system a regular ruler was used and an object was translated over a distance of 5 cm in 
steps of 0.5 cm. The ADC signals were acquired during 6 seconds for each distance (Figure 19) and 
their mean (for each distance) were calculated. Using the mean ADC values for each distance a 
linear calibration function of distance as function of the ADC values was created.   
 
 
Figure 18 – Experimental setup used to validate the US system. The US system was validated with the dynamic thorax 
phantom “CIRS” (Universal Medical, model #008A). 
 
Figure 19 – Acquired ADC values for 11 different distances spaced 0.5 cm from each other during a period of 6 seconds 
with the US system. The ADC values for each distance were used to create a calibration function to convert the output of 
the US system in ADC values to distance.  
3.4.2. Stage translation validation 
To measure and evaluate the stage motion in the longitudinal (z axis), lateral (x axis) and vertical 
(y axis) directions, protocols with different numbers of CPs, 5, 10, 20, 50, 100, 150 and 180, were 
created. The experimental setup used to measure the stage movement in the different directions 
is represented in Figure 20. The total stage movement was kept constant at 2 cm for all the 3 
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directions and the irradiation time was 120 seconds. The longitudinal stage movement was also 
measured for a beam-on time of 60 seconds and a translation of 3 cm.  
 
Figure 20 – Experimental setup for the US measurements. To measure the stage movement in the longitudinal direction 
(z axis), the US sensor (in red) was attached to the gantry, to measure the stage movement in the lateral direction (x 
axis) the US sensor was attached to the optical camera and to measure the stage movement in the vertical direction (y 
axis) the US sensor was attached to the flat panel detector. The US sensor position is stationary and the reflective object, 
represented by the box, was attached to the moving stage. 
The stage speed between CPs was also evaluated for the different directions for a stage translation 
of 2 cm and an irradiation time of 120 seconds. The stage speed was calculated for one case, 10CP. 
For higher numbers of CPs the steps between CPs were not discernable anymore. The stage speed 
was calculated based on the data acquired with the US system. Figure 21 shows that the steps that 
represent the stage movement between CPs are clearly distinguishable for 10 CPs.  The speed of 
the stage for each step is given by the slope (m) of the regression function (black solid 
line):  𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 =  𝑚 ∗ 𝑡 + 𝑏, as shown in Figure 21. For each step a different regression function 
needs to be calculated. 
 
Figure 21 – Representation of a step of a stage translation of 2 cm and an irradiation time of 120 seconds for 10 CPs. 
The data was acquired with the US system and each step represents the stage movement between CPs. For each step a 
different regression function is calculated and the slope (m) of each regression function gives the speed of the stage for 
the different steps. 
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3.5. Homogeneous dose distributions 
 
3.5.1. Required distance between CPs  
It is known that increasing the number of beams used in the treatment plan increases the 
homogeneity of the dose distribution (Motomura et al., 2010). Here, the required spatial 
separation between CPs was studied with the aim of mimicking a homogeneous dose distribution 
for 3 circular fields with diameters of 2, 5 and 10 mm. For each field dimension, cases with 
different numbers of CPs were simulated, with a total stage translation of 2 cm for the 5 and 10 
mm circular beams, and a total stage movement of 1 cm for the 2 mm circular beam. To evaluate 
the dose homogeneity, the standard deviation of a region of interest in the central region of the 
dose distribution was calculated. A region of interest for a beam size of 10 mm is represented in 
figure 22. Different regions of interest dimensions were considered for the 3 different fields. 
Regions of interest of 0.0425 cm2, 0.1214 cm2 and 0.3192 cm2 were considered for the 2 mm,              
5 mm and 10 mm circular beams, respectively.  
 
Figure 22 – a) Dose distribution for the 10 mm circular beam using 100 CPs. b) Mask used to define the region of 
interest.  
The required number of CPs (#CP) can be calculated using equation 4. 
                                                         #CP=round (
Total Distance
Space between CP
) + 1                                  [4] 
 
3.5.2. Evaluation of dose distribution during irradiation 
In this section the possibility of delivering complex dose distributions using the XRAD-225Cx 
platform was investigated. As a first step the stage motion was studied while the gantry was 
stationary. Following this and as a second step, simultaneous stage and gantry movement during 
irradiation was studied.  
3.5.2.1. Stage translation & Stationary gantry 
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The evaluation of the stage translation, while the gantry was stationary, was based on dose 
distributions. To assess the dose distributions, radiochromic EBT3 films (Ashland, Lot # 
04151402) were placed on the animal stage perpendicularly to the beam. The EBT3 films were 
scanned 24 hours (enough time for the polymerization process occurs) after irradiation using an 
Epson Perfection V750 Pro flatbed scanner and the Epson Scan software v3.83 (Seiko Epson 
Corporation, Nagano, Japan). Each film was scanned separately in the center of the scanner. The 
scanned images were saved as triple channel (Red-Blue-Green) TIFFs with a spatial resolution of 
225 DPI and an intensity resolution of 48 bit (16 bit per color channel). For each image the optical 
density was converted to dose using the triple channel method (Hoof, 2012). Dose distributions 
were evaluated for dose delivery plans using 20, 50, 100, 130, 150 and 180 CPs, for longitudinal 
and for lateral stage translations. Different treatment protocols were created with a total stage 
translation of 2 cm and an irradiation time of 120 seconds. To compare the dose distribution 
between the longitudinal and lateral stage translation the gamma analyses method was used with 
a dose difference criteria of 3% and a distance to agreement criteria of 0.5 mm.  
3.5.2.2. Stage translation & Gantry rotation 
To investigate the simultaneous movement of the gantry and the stage in the longitudinal 
direction, protocols with 25, 50 and 100 CPs were created. Protocols with 25, 50 and 100 CPs 
were created to evaluate the feasibility of delivering complex dose distributions based on 
treatment plans with low and high number of CPs. For each protocol the number of CPs used for 
the translational movement was the same used for the gantry movement. The stage movement 
was fixed to 2 cm, the irradiation time was 200 seconds and the gantry rotation was set to one full 
rotation per treatment protocol. The dose distributions were measured with radiochromic EBT3 
films (Ashland, Lot # 04151402). The EBT3 films were placed between 2 slabs of water equivalent 
material in parallel to the stage.  
To evaluate the different delivered treatments, the delivered (measured) dose distributions were 
compared with simulations through the gamma analyses method. For the treatments where the 
stage was moving but the gantry was stationary, the simulations were based on CBCT images with 
an isotropic voxel spacing of 0.2 mm. For the treatments where both stage and gantry were 
moving simultaneously, the simulations were based on CBCT images with an isotropic voxel 
spacing of 0.1 mm. The simulations were performed using SmART-Plan. The gamma criteria used 
for the comparison in the first case was a dose difference of 3% and a distance to agreement of 0.5 
mm. The gamma criteria used for the comparison for the second case was a dose difference of 5% 
and a distance to agreement of 1.0 mm. A circular field with a diameter dimension of 10 mm was 
used for both cases. 
 
3.6. Need of additional spatial degrees of freedom in small animal radiotherapy 
Rotating the stage in the xz plane and the grantry in the y plane (figure 23 a)) enables the delivery 
of beams from any desired angle. 
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Figure 23 – a) Spherical coordinates. b) The three orthogonal anatomic planes of the rat body. 
To assess if beams delivered from different directions in small animal radiotherapy improve dose 
distributions, two different cases were considered. The treatment plans were based on CBCT 
images with an isotropic voxel spacing of 0.1 mm. For the two cases a prescription dose of 4 Gy to 
the tumor was used. In both cases, treatment plans with different beam configurations were 
simulated and all the treatments were scaled to the same V95% of the tumor. Here, V95% is defined 
as the fraction of the tumor volume receiving at least 95% of the prescribed dose. Circular beams 
with a diameter of 5 mm were used for the simulations and the beams were linked to the same 
machine isocenter for all the different treatment cases. Treatment plans were evaluated based on 
DVHs and Dose-Volume (DV) metrics, Dmean, Dmax, D5% and D1%. The simulated treatment plans 
with beams delivered from different directions were compared with a standard treatment plan 
used in current pre-clinical practice, which is usually done with one or two beams delivered from 
the axial plane (rotating gantry axis) (Figure 23 b)). 
3.6.1. Mouse Glioblastoma case 
The first case consisted of a mouse glioblastoma where only two structures were considered, the 
tumor and the normal brain tissue, since the lack of imaging contrast between tissues made the 
tissue segmentation nearly impossible. The first treatment plan consisted of two parallel opposed 
beams (considered standard treatment). For the second treatment plan, a full 360 degree arc in 
the axial plane was simulated. In the third treatment case, a beam configuration consisting of a 
beam rotated 60 degrees from the axial plane in the cranio-caudal direction was considered.  
3.6.2. Mouse Right Lung tumor case 
The second case was a tumor located in the right lung of a mouse. In this case seven organs at risk 
located in the thorax were considered. The delineation of the tumor and the organs at risk was 
made by a qualified radiation oncologist. Three treatment plans with different beam 
configurations were simulated. The first treatment case consisted of two beams delivered in the 
axial plane. One of the beams was positioned 9 degrees from the vertical axis and the other beam 
was positioned at -99 degrees from the vertical axis. In the second beam configuration, three 
beams were positioned at 30, 40 and 50 degrees from the axial plane in the cranio-caudal 
direction. For the last treatment case eleven beams were delivered from multiple directions.  
Specific information about the number of beams, beam angles and beam directions used per 
treatment case can be found in Appendix C.   
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3.7. Treatment based on stage translation 
As a final step, a treatment based on stage movement for a real mouse case with a tumor in the 
right lung, where 7 structures at risk were considered, was simulated. To simulate a treatment 
based on stage movement the beam size has to be smaller than the target. 
To define the different stage positions, as a first step, the slices in the z direction (axial slices) 
containing the target structure (i.e. tumor) are selected. After all the  z positions are selected and 
based on the  contours  of the target structure, a  grid  with  the  x  and  y  positions per  slice  is 
created for each axial slice, originating a x, y and z value for each stage position (figure 24). The 
treatment plans simulations were based on CBCT images with an isotropic voxel spacing of 0.1 
mm.  
A treatment plan based on stage translation was compared with a similar treatment plan based on 
a single stage position with a beam size bigger than the tumor. For the case based on stage 
translation 316 different stage positions were considered, with a beam of 2 mm being delivered 
from the top. For the case based on a single stage position, a configuration of two beams was 
considered where one beam was delivered from the top and the other one was deviated 5 degrees 
from the vertical axis. To collimate the beams, a circular field with a diameter of 5 mm was used.  
For the two simulations a prescription dose of 4 Gy to the tumor was used and both treatments 
were scaled to the same V95% of the tumor. 
 
Figure 24 – Schematic representation of the process to define the different stage positions of a treatment based on stage 
movement for a mouse tumor case. As a first step slices in the z direction containing the target structure (red structure) 
are selected. After all the  z positions being selected and based on the  contours  of the target structure  a  grid  with  the  
x  and  y  positions per  slice  is created for each axial slice, originating a x, y and z value for each stage position.   
Specific information about the number of beams, beam angles and beam direction used per 
treatment case can be found in Appendix D.   
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4. RESULTS 
 
4.1. Stage positioning validation 
 
4.1.1. Calibration and Validation of the US sensor 
Measured calibration data and the fitted calibration function of distance as function of ADC values 
are both presented in figure 25. Blue circles indicate the mean ADC values acquired with the US 
system for all calibration distances. The resulting equation for the linear fit is:  
                                                     𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 =  1.35 x 10−3 ∗ 𝐴𝐷𝐶 +  15.01                                             [5] 
where distance is in cm. The high value of the R2 indicates that the calibration function fits well to 
the calibration data with low residual values. 
The theoretical sinusoidal movement of the CIRS phantom and the movement measured with the 
US system are plotted in figure 26. The amplitude of the sinusoidal movement of CIRS phantom 
was defined to 1.5 cm and the period of the movement was set to 4 seconds. The results indicate a 
good overlap between the theoretical sinusoidal translation and the translation measured with 
the US system, indicating a trustful measurement of a real dynamic translation. 
 
Figure 25  – Calibration curve and fitted linear equation to convert the acquired signal with the US system in ADC 
values to distance in cm. Blue circles represent the mean ADC values for each distance and the red line represents the 
fitted linear function. 
 
Figure 26 – Validation data for the US system. Representation of the (red) measured inserted sinusoidal wave with an 
amplitude of 1.5 cm and a periodic movement of 4 seconds and (blue) the measured sinusoidal wave with the US 
system.  
2015/2016 
 
28 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for Delivering Complex Dose Distribution 
4.1.2. Stage translation validation 
Figure 27, 28, and 29 show the stage translation measurements for the longitudinal, lateral and 
vertical directions, respectively, obtained with the US system for 5, 10, 20, 50, 100, 150 and 180 
CPs. For a small number of CPs (up to 20), the distance between CPs is higher making the CPs 
distinguishable. For higher numbers of CPs, the stage translation resembles a continuous 
translation. 
 
Figure 27 – Stage translation in the longitudinal direction for different numbers of CPs. The stage position was 
measured with the US system and the total distance was set to 2 cm for an irradiation time of 120 seconds. 
 
Figure 28 - Stage translation in the lateral direction for different numbers of CPs. The stage position was measured with 
the US system and the total distance was set to 2 cm for an irradiation time of 120 seconds. 
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Figure 29 - Stage translation in the vertical direction for different numbers of CPs. The stage position was measured 
with the US system and the total distance was set to 2 cm for an irradiation time of 120 seconds. 
The total stage translation measured for different numbers of CPs for each direction is presented 
in figure 30 a). Each line represents the mean total stage translation for the different directions. 
The mean total stage translation was 1.949 ± 3.848*10-03 cm, 1.988 ± 5.350*10-03 cm and 1.985 ± 
4.504*10-03 cm for the longitudinal, lateral and vertical direction respectively. Coefficients of 
variance (COV) were calculated for the stage translation in the different directions.  COVs indicate 
the ratio between the standard deviation of the total stage translation and the mean for the 
different numbers of CPs. The coefficient of variance for the stage translation in the longitudinal 
direction was 0.20%, 0.27% for the lateral direction and 0.23% for the vertical direction. The 
obtained low COV values indicate that the stage translation is not dependent of the number of CPs 
used. 
Figure 30 b) shows the total stage translation error per number of CPs for the three directions. 
The error was calculated between the total measured translation and the one specified in the 
protocol, 2 cm, for the different numbers of CPs. The lines represent the mean error of the stage 
translation for each direction. The longitudinal direction showed the highest mean error, which 
was 2.56% compared to mean errors of 0.62% and 0.77% for the lateral and vertical direction, 
respectively. Among all the directions and numbers of CPs, the stage translation error was always 
below 3%, suggesting that the stage reproduces well what is specified in the protocols. 
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Figure 30 – a) Total measured stage translation for different numbers of CPs in the 3 different directions. The lines 
represent the total mean stage translation for each direction. b) Total stage translation error for the different CPs for the 
3 different directions. The lines represent the mean stage translation error value in each direction.    
 
Stage speed  
The mean stage speed per step for the longitudinal, lateral and vertical directions for 10 CPs is 
shown in figure 31. The horizontal lines represent the mean stage speed for each direction. The 
mean stage speed translation in the longitudinal direction was 0.332 ± 4.874*10-03 cm/s with a 
COV of 1.46%. In the lateral direction the mean stage sped was 0.324 ± 1.221*10-02 cm/s with a 
COV of 3.78%. For the vertical translation the mean stage speed was 0.334 ± 8.544*10-03 cm/s 
with a COV of 2.56%. The maximum speed difference between the different directions was 0.051 
cm/s. The results of the stage speed show that the stage moves between CPs with similar speeds 
revealed by the calculated COV values, which demonstrates the stability of the stage during a 
treatment based on CPs.  
 
 
Figure 31 – Measured stage speed in cm/s per step for the 3 different directions for 10CP. The horizontal lines 
represent the mean stage speed value for each direction. 
The total longitudinal stage translation for three different combinations of stage translation 
distances and irradiation times are shown in figure 32 a). The first combination was a translation 
of 2 cm over a period of 60 seconds. The second combination was a translation of 2 cm over a 
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period of 120 seconds. The third combinations was a translation of 3 cm over a period of 120 
seconds. The horizontal lines represent the mean total stage translation for different number of 
CPs and for each combination. The mean total stage translation for the first combination was 
1.945 ± 2.295*10-03 cm with a COV of 0.12%, for the second combination was 1.949 ± 3.848*10-03 
cm with a COV of 0.20% and for the third combination was 2.931 ± 4.077*10-03 cm with a COV of 
0.14%. Figure 32 b) shows the total stage translation error per number of CPs for the three 
different combinations and the lines represent the mean error of the stage translation. The 
maximum mean error of 2.7% was observed for a translation of 2 cm over an irradiation period of 
60 seconds. The total stage translation error for all cases varied between 2.1% and 2.9%. The low 
COV values and the stage movement errors below 3% over all the three combinations indicate 
that the stage moves in the same way regardless the number of CPs used, the stage translation 
distance and irradiation time.  
 
Figure 32 – a) Total measured stage translation in the longitudinal direction for different number of CPs and for 
different stage translation distances and irradiation times. The lines represent the mean total stage translation for the 
different combinations. b) Mean total stage translation error for the different considered CPs for the 3 different 
combinations. The horizontal lines represent the mean stage translation error for the different combinations.    
The stage speed in the longitudinal direction for the three different combinations for 10 CPs is 
presented in Figure 33. The lines represent the mean stage speed for the different combinations. 
For the first combination, the mean stage translation speed was 0.332 ± 7.19*10-03 cm/s with a 
COV of 2.17%. For the second combination the mean stage speed was 0.324 ± 1.221*10-02 cm/s 
with a COV of 3.77%. For the third combination the mean stage speed was 0.406 ± 3.965*10-03 
cm/s with a COV of 2.28%. The maximum speed difference between the different translation 
combinations was 0.026 cm/s.  The low COV values indicate that the stage moves similarly 
between CPs regardless the combination of stage translation distance and irradiation time used. 
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Figure 33 - Measured stage speed in cm/s per step in the longitudinal direction for different number of CPs and for 
different stage translations and irradiation times for 10CP. The horizontal lines represent the mean stage speed value 
for the different combinations. 
 
4.2. Homogeneous dose distributions 
 
4.2.1. Required distance between CPs  
The standard deviation (std) of regions of interest for dose distributions delivered using different 
numbers of CPs for three different circular fields are shown in figure 34. To have a reasonable 
control of the treatment outcome, the relative standard deviation of the mean dose in the target 
volume should be less than 5% and, if possible, as small as 3% (Brahme, 1984). Table 3 shows the 
distances between CPs for a 2 mm, 5 mm and 10 mm circular fields to achieve a dose distribution 
COV of 3% and 5%.  
 
 
 
Figure 34 – Standard deviation of the dose distribution as function of the distance between CPs for 3 different circular 
fields. The black lines represent a standard deviation of 3% and 5%. 
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Table 3 – Required distance between CPs for 3 different circular fields and for a std in the region of interest of 3% and 
5%.  
 Required distance between CPs’ (mm) 
std (%) 2 mm beams 5 mm beam 10 mm beam 
3 0.67 mm 1.19 mm 1.30 mm 
5 1.12 mm 1.32 mm 1.81 mm 
 
4.2.2. Evaluation of dose distribution during irradiation 
 
4.2.2.1. Stage translation & Stationary gantry 
The gamma analyses between dose distributions for the stage translation in the longitudinal and 
lateral direction for the same number of CPs are presented in Figure 35. The gamma criteria used 
for the comparison were a dose difference of 3% and a distance to agreement of 0.5 mm. The 
highest gamma fail rate was observed for 20CP. The low gamma fail rate values indicate a similar 
dose distribution for the stage translation in the longitudinal and lateral direction, meaning that 
the stage moves similarly in both directions. 
 
Figure 35 – Gamma analyses of measured dose distribution with EBT3 films between the stage translation in the 
longitudinal direction and lateral direction for 6 different numbers of CPs. For both directions the total stage translation 
was set to 2 cm, the irradiation time was 120 seconds and a 10 mm circular field was used. The gamma criteria used for 
the comparison were a dose difference of 3% and a distance to agreement of 0.5 mm. 
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Figures 36, 37, 38 and 39 present the measured and the simulated dose distribution for 20, 50, 
100 and 130 CPs, respectively, for a longitudinal stage translation of 2 cm over an irradiation 
period of 120 seconds. The gamma analyses are also presented for the different numbers of CPs. 
The gamma criteria used for the comparison were a dose difference of 3% and a distance to 
agreement of 0.5 mm. The highest gamma fail rate was observed for 20CPs. For the rest of the 
cases the gamma fail rate was zero, indicating a high agreement between the measurements and 
the simulations.  
20 CPs - Longitudinal translation 
 
Figure 36 – Representation of the dose distribution measured with an EBT3 film and the simulated dose distribution as 
simulated on SmART-Plan for 20 CP and a total longitudinal stage translation of 2 cm over an irradiation period of 120 
seconds. A circular field with a diameter of 10 mm was used for collimation. The gamma analyses is also presented. The 
gamma criteria used for the comparison were a dose difference of 3% and a distance to agreement of 0.5 mm. 
 
50 CPs - Longitudinal translation 
 
Figure 37 - Representation of the dose distribution measured with an EBT3 film and the simulated dose distribution as 
simulated on SmART-Plan for 50 CP and a total longitudinal stage translation of 2 cm over an irradiation period of 120 
seconds. A circular field with a diameter of 10 mm was used for collimation. The gamma analyses is also presented. The 
gamma criteria used for the comparison were a dose difference of 3% and a distance to agreement of 0.5 mm. 
100 CPs - Longitudinal translation 
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Figure 38 - Representation of the dose distribution measured with an EBT3 film and the simulated dose distribution as 
simulated on SmART-Plan for 100 CP and a total longitudinal stage translation of 2 cm over an irradiation period of 120 
seconds. A circular field with a diameter of 10 mm was used for collimation. The gamma analyses is also presented. The 
gamma criteria used for the comparison were a dose difference of 3% and a distance to agreement of 0.5 mm. 
 
130 CPs - Longitudinal translation 
 
Figure 39 - Representation of the dose distribution measured with an EBT3 film and the simulated dose distribution as 
simulated on SmART-Plan for 130 CP and a total longitudinal stage translation of 2 cm over an irradiation period of 120 
seconds. A circular field with a diameter of 10 mm was used for collimation. The gamma analyses is also presented. The 
gamma criteria used for the comparison were a dose difference of 3% and a distance to agreement of 0.5 mm. 
Resulting dose profiles for the measured and simulated dose distributions for different numbers 
of CPs are presented in Figure 40. Dose profile lines were calculated along the longitudinal 
direction, as it can be observed on the dose distribution image present in Figure 40. This figure 
shows a good agreement between the measured and the simulated dose profiles for all cases.  
2015/2016 
 
36 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for Delivering Complex Dose Distribution 
  
Figure 40 – Measured and simulated longitudinal dose profiles for 20, 50, 100 and 130 CPs for a total longitudinal stage 
translation of 2cm over an irradiation period of 120s. The dose profile line for the measured dose profile for 20 CPs is 
represented in white. 
 
4.2.2.2. Stage translation & Gantry rotation 
Figure 41, 42 and 43 show the measured and the simulated dose distributions for 25, 50 and 100 
CPs, respectively, and the gamma analyses between both dose distributions, for a longitudinal 
stage translation of 2 cm and a simultaneous full gantry arc revolution. Both the stage translation 
and full gantry rotation were performed using the same number of CPs. The gamma criteria used 
for the comparison were a dose difference of 5% and a distance to agreement of 1.0 mm. The fail 
rates are also shown for each CP comparison. The highest gamma fail rate was observed for 25 
CPs. For the rest of the cases the gamma fail rate was zero, meaning that there is not a single pixel 
failing in the gamma analyses. These results reveal a high agreement between the measurements 
and the simulations.  
25 CP - Longitudinal translation – 25 CP – Gantry revolution
 
Figure 41 - Measured dose distribution with EBT3 film and the simulated dose distribution using SmART-Plan for 25 
CPs for a total longitudinal stage translation of 2 cm and a full gantry arc revolution over an irradiation period of 200 
seconds. The gamma criteria used for the comparison was a dose difference of 5% and a distance to agreement of 1.0 
mm. 
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50 CP - Longitudinal translation – 50 CP – Gantry revolution 
 
Figure 42 - Measured dose distribution with EBT3 film and the simulated dose distribution using SmART-Plan for 50 
CPs for a total longitudinal stage translation of 2 cm and a full gantry arc revolution over an irradiation period of 200 
seconds. The gamma criteria used for the comparison was a dose difference of 5% and a distance to agreement of 1.0 
mm. 
100 CP - Longitudinal translation – 100 CP – Gantry revolution 
 
Figure 43 - Measured dose distribution with EBT3 film and the simulated dose distribution using SmART-Plan for 100 
CPs for a total longitudinal stage translation of 2 cm and a full gantry arc revolution over an irradiation priod of 200 
seconds. The gamma criteria used for the comparison was a dose difference of 5% and a distance to agreement of 1.0 
mm. 
 
4.3. Need of additional spatial degrees of freedom in small animal radiotherapy 
 
4.3.1. Mouse Glioblastoma case 
Different treatment plans with different beam configurations were simulated for a mouse 
glioblastoma case and are presented in figure 44. Two volumes of interest were delineated, the 
normal brain (V = 320 mm3) and the brain tumor (V = 4 mm3). Figure 45 shows the DVHs for the 
glioblastoma and for the normal brain for the three simulated treatment cases. When analyzing 
the brain DVH for the different cases, the second case delivers a higher dose to the normal tissue 
brain. When comparing the brain DVH between case 1 (standard treatment) and case 3, there is 
no visible difference. The DV metrics for the brain for the three cases are shown in table 4. Case 2 
presents a higher mean dose delivered to the normal brain, but case 3 presents a higher D1%, a 
higher maximum dose (Dmax) and a higher D5%. 
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Figure 44 – Different views of the dose distribution for 3 treatments plans for a mouse brain tumor case. The 
prescription dose to the tumor was 4Gy. For each case, the first dose distribution image (left) represents a slice in the 
axial plane, the second dose distribution image (middle) represents a slice in the sagittal plane and the third dose 
distribution image (right) represents a slice in the coronal plane. 
 
Figure 45 – DVHs obtained for glioblastoma and normal brain for the 3 considered treatment cases represented by 
different lines. The DVHs for the different cases were scaled to the same V95% of the tumor. The vertical black solid line 
indicates the prescription dose to the tumor, 4 Gy. 
Table 4 – DV metrics of the normal brain tissue for the 3 treatment cases. 
 
Brain 
D (Gy) Case 1 Case 2 Case 3 
Dmean 1.01 1.30 0.99 
D5% 4.07 4.06 4.16 
Dmax 4.46 4.49 4.67 
D1% 4.18 4.18 4.33 
 
                                       Axial     Sagittal           Coronal 
 
Case 1 
Parallel opposed 
beams 
Case 2 
Full 360 degree 
arc beam 
Case 3 
Non-coplanar 
beam 
Glioblastoma 
Brain 
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4.3.2. Mouse Right Lung tumor case 
Different treatment cases for a mouse lung tumor were simulated. The respective overview is 
shown in Figure 46. Seven different structures were considered and they can be visualized in 
figure 46, delineated with different colors. The lung tumor (V=30 mm3) was located in the right 
lung (V=220 mm3). Figure 47 shows the DVHs for the tumor and for the 6 OARs for the 3 
treatment cases. When analyzing the OAR DVHs for the different cases, it must be highlighted that 
case 3 is the one delivering more dose to the heart and stomach. The treatment plan from case 2 is 
the only treatment plan delivering zero dose to the right lung. This treatment plan also delivers 
less dose to the left lung but delivers more dose to the liver. Different DV metrics for the 6 OAR for 
the 3 cases are shown in Figure 47. The biggest differences on the DV metrics are present for case 
3, where there is no dose delivered to the left lung and there is a higher dose delivered to the liver.  
 
                   
                   
                    
Figure 46 – Different views of the dose distribution for 3 treatments plans for a lung tumor case with a prescription 
dose of 4 Gy. The first dose distribution image represents a slice in the axial plane, the second dose distribution image 
represents a slice in the sagittal plane and the third dose distribution image represents a slice in the coronal plane. 
                        Axial                     Sagittal                   Coronal 
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Figure 47 - DVHs obtained for the lung tumor and for the different considered OARs, for the 3 considered treatment 
cases. The DVHs for the different cases were scaled to the same V95% of the tumor. The vertical black solid line 
indicates the prescription dose to the tumor, 4 Gy. 
 
Figure 48 – DH metrics of the OARs obtained for the lung tumor, for the 3 treatment cases. 
 
4.4. Treatment based on stage translation 
A treatment case based on different stage positions was simulated for a mouse lung tumor case 
and the resulting dose distribution is presented in Figure 49 as case 2. In Figure 49 it is also 
represented another case, case 1, based on a single stage position with a similar beam 
configuration of case 2 for comparison. Figure 49 shows similar dose distributions for both cases. 
Looking to the coronal view is visible some degree of conformity of the dose to the tumor when a 
treatment based on a stage translation is used. The DVHs of the tumor and the 6 OARs for the 2 
treatment cases are presented in Figure 50. Figure 50 shows a higher delivered dose to the tumor, 
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right lung and heart when the treatment is based on multiple stage positions. For the remaining 
OAR the DVHs are similar. 
 
                          
Figure 49 - Different views of the dose distribution for 2 different treatments plans, the first one based on a single stage 
position and the other based on multiple stage positions, for a lung tumor case with a prescription dose of 4 Gy. The first 
dose distribution image represents a slice in the axial plane, the second dose distribution image represents a slice in the 
sagittal plane and the third dose distribution image represents a slice in the coronal plane. 
 
                             
Figure 50 - DVHs obtained for the lung tumor case and for the different considered OARs, for 2 different treatments, the 
first one based on a single stage position and the other based on multiple stage positions. The DVHs for the different 
cases were scaled to the same V95% of the tumor. The vertical black solid line indicates the prescription dose to the 
tumor, 4 Gy. 
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5. DISCUSSION 
The feasibility of delivering complex dose distributions through stage and gantry movement was 
investigated in this thesis. The delivery of complex dose distributions is accomplished by 
treatment protocols based on different numbers of CPs. The stage translation was investigated 
and according to the results regardless of the stage translation direction the movement is not 
dependent on the number of CPs used. The results also show a stage movement between CPs with 
similar speeds, which demonstrate the stability of the stage translation during a treatment based 
on CPs. The stage translation is neither dependent of the irradiation time nor the stage translation 
distance. The high agreement between the simulations and measurements indicate that the stage 
reproduces in the correct way what is specified in the protocols. Initially, during the first 
experiments, was discovered that the delivered dose was increasing with the number of CPs. This 
increase was later explained by the increase of the irradiation period when the number of CPs 
also increases (Appendix E). Once the error was found, an update was performed to the small 
animal platform and the error was fixed. The results presented here, in this thesis, are relative to 
the small animal platform after the update.  
The need of spatial degrees of freedom in small animal radiotherapy, where treatments based on 
beams delivered from multiple directions instead of beams only delivered from angles allowed by 
the gantry rotation for the mouse glioblastoma case, showed that there is not a significant 
difference between a treatment based on a standard treatment plan used in current pre-clinical 
practice (case 1) and a treatment based on a beam delivered from an angle not allowed by the 
gantry (case 3). The high dose delivered to the normal brain seen for case 2, is due to the use of a 
full 360 arc beam which irradiates a higher volume of the normal brain. Based on the mouse 
glioblastoma treatment case the delivery of beams from additional angles do not improve the 
treatment. Nevertheless, is important to be aware that this is a simple case where just two 
structures were considered. Regarding the mouse right lung tumor case there is a clear 
improvement of the DVHs of the OARs when treatments based on beams delivered from 
directions not allowed by the gantry (non co-planar beams) are used. The main difference is seen 
for the dose delivered to the left lung since with the correct beam geometry this structure can be 
completely avoided.  This thesis shows a case where additional degrees of freedom may not 
improve the treatment but in contrast a treatment improvement is also shown when beams 
delivered from different directions are used. In this way, more cases with different types of cancer 
and cancer geometries need to be investigated in order to better understand when the use of 
additional degrees of freedom is translated in a real improvement of the treatment plans. 
The mouse lung tumor treatment simulation based on stage translation showed higher delivered 
doses to some structures when compared with a treatment based on a single stage position. This 
can be explained by dose overlapping on some stage positions which creates hot spots increasing 
the dose on those structures.  The case studied here was based on 316 different stage positions 
and trying to simulate a treatment with such a high number of different stage positions is time 
and memory consuming and is important to keep in mind that the animal is under anesthesia 
during the entire process, which includes the time to perform the simulations. Another important 
aspect is the delivery of the treatment itself, which if it was based on so many stage positions the 
irradiation would be nearly impossible. In this way it is extremely important to create a beam 
optimizer not only capable of beam optimization but also capable of reducing the number of stage 
positions.  
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6. CONCLUSION  
In this thesis complex dose distributions were delivered with treatments based on stage and 
gantry movement. This was done through the use of CP based treatment plans for the ﬁrst time in 
small animal radiotherapy. The stage positioning and translation during irradiation was proven to 
be accurate and reliable and the irradiator can handle large number of CPs without problems. The 
study of the dose distributions showed a high agreement between the film measurements and 
simulations. According to what was investigated in this thesis, it is safe to say that SmART 
platform is capable of delivering complex dose distributions based on stage and gantry 
movement. 
 
7. FUTURE PERSPECTIVES 
Hardware for precision image-guided small animal radiotherapy is evolving rapidly and catching 
up with clinical irradiation capabilities. These improvements of pre-clinical radiotherapy research 
platforms require equally improving software and algorithms to plan, evaluate and control the 
hardware. However, since treatment goals and restrictions in pre-clinical research can be vastly 
different from the clinical setting, it is not necessarily the case that pre-clinical research platforms 
require or need to pursue the same development path their clinical counterparts have gone 
through. This can be applied, for example, to the beam-shaping multileaf collimator on an 
accelerator used in clinical practice, which is essential in radiotherapy, but would be very hard to 
miniaturize for small animal radiotherapy platforms. 
Data indicates that treatments capable of delivering beams from additional directions may 
provide benefits over standard treatments, if the correct beam geometry and configuration are 
used. Nevertheless more mice tumor cases with different tumors locations, sizes and geometries 
need to be investigated. To better and faster investigate this issue, a beam optimizer capable of 
beam weights optimization and of automatically choosing the optimum beams combination and 
geometry is desirable. 
With a gantry and stage capable of rotating 360 degrees the target can be irradiated from any 
desired direction and angle, which brings a new set of possibilities. In this way, it is important to 
outline some priorities and define what are the main OAR to avoid and also define dose 
constraints for animal studies. Furthermore, it is also important to understand and prioritize, for 
each individual case, what is more important: trying to avoid some OAR or irradiate the tumor 
with the maximum possible dose accuracy. All of these are questions that need to be addressed 
and that are very important to improve radiotherapy studies in small animals. Along with this, 
better imaging techniques that enable better tissue segmentation are crucial to help to answer all 
these questions. Recently, some advances have been made in this particular field with the 
development of dual Energy CT in small animal radiotherapy (Schyns et al., 2016).   
In comparison with a treatment based on a single stage position, the simulations of treatments 
based on multiple stage positions showed high delivered doses to some structures. A possible way 
to compensate for this, could be through a treatment plan optimizer capable of delivering 
automatically homogeneous dose distributions avoiding the creation of hot spots and reduce as 
much as possible the number of different required stage position. It would also be interesting to 
investigate the possibility of achieving treatments with similar outcomes/qualities when 
treatments based on stage translation and gantry rotation are compared with treatment based on 
2015/2016 
 
44 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for Delivering Complex Dose Distribution 
stage and rotation, which it is not possible yet. Regardless the preferable chosen technique in both 
ways to maximize the benefits of the capabilities of image-guided small animal radiotherapy 
platforms, treatment planning automation and inversion is required to deliver more complex dose 
distributions. 
With gantry and stage movement all geometric degrees of freedom can be achieved. In small 
animal radiotherapy, the adjustment of the voltage potential of the X-Ray tube is also possible, 
which allows the altering of the maximum photon energy. By lowering the photon energy, the 
dose gradient in the animal will change compared to the standard photon energy. Hence, distant 
organs at risk are more likely to be spared. It would also be interesting to understand if treatment 
plans based on lower kV photon energies could improve the treatment. 
It is also important to have in mind that, with stage and gantry movement, it is possible to deliver 
heterogeneous dose distributions, making dose painting studies a possible next step in small 
animal radiotherapy. Heterogeneous doses can also be achieved by changing photon’s energy 
during treatment. In this way, treatments with a dynamic change in photon’s energy could be a 
different/complementary approach to the gantry and stage movement. 
As final words, along with the development and improvement of small animal radiotherapy 
platforms and small animal cancer models, has come the growth in fundamental knowledge and 
greater translational insight, that should further extend our still incomplete genetic and molecular 
understanding of cancer. These new knowledges can later be used to ensure better methods for 
cancer detection, diagnosis and treatment. Currently, research and introduction of new drugs and 
treatments into clinical practice in terms of safety and efficacy is still far away from a point where 
research and validation should preferably be done without the use of small animals.  
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APPENDIX A – TREATMENT PROTOCOL 
Here is presented an example of a protocol used to evaluate the stage positioning of the XRAD-
225Cx device. This protocol delivers a treatment with a total stage translation of 2 cm in the 
longitudinal direction divided by 11 CPs.   
[Protocol] 
Name= Protocol 1  
Version=1  
Description= total stage translation = 2cm; direction = longitudinal; number of 
control points = 10 
 
[Beam0] 
BeamNumber=1  
BeamName=Beam 1  
BeamDescription=Beam 1  
UserInstructions=lln  
BeamType=STATIC  
RadiationType=PHOTON  
PrimaryDosimeterUnit=MINUTE  
FinalCumulativeMetersetWeight=100  
BeamOnTime=120 
 
[Beam0 - ControlPoint0] 
CumulativeMetersetWeight=0.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=0.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint1] 
CumulativeMetersetWeight=10.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-2.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint2] 
CumulativeMetersetWeight=20.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-4.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint3] 
CumulativeMetersetWeight=30.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-6.00 
TableTopLateralPosition=0.00 
 
2015/2016 
 
49 
The Feasibility of SmART (Small Animal Radiation Therapy) Platform for Delivering Complex Dose Distribution 
[Beam0 - ControlPoint4] 
CumulativeMetersetWeight=40.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-8.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint5] 
CumulativeMetersetWeight=50.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-10.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint6] 
CumulativeMetersetWeight=60.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-12.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint7] 
CumulativeMetersetWeight=70.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-14.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint8] 
CumulativeMetersetWeight=80.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-16.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint9] 
CumulativeMetersetWeight=90.00 
NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-18.00 
TableTopLateralPosition=0.00 
 
[Beam0 - ControlPoint10] 
CumulativeMetersetWeight=100.00 
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NominalBeamEnergy=0.010 
NominalTubeCurrent=13 
SpotSize=LARGE 
GantryAngleIEC=0 
GantryRotationDirection=NONE 
TableTopVerticalPosition=0.00 
TableTopLongitudinalPosition=-20.00 
TableTopLateralPosition=0.00 
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APPENDIX B – US NOISE FILTERING 
The raw output signal from the US system, represented in blue in figure 51, presents some noise. 
The noise can be decreased by adding a capacitor to the US system. In this way the output of the 
US system without capacitor, with a 10 nF capacitor and a 100 nF capacitor were compared. 
Figure 51 shows a clear reduce of the US signal noise when a capacitor is added to the circuit. 
Looking to Table 5, the US system presenting the smallest mean standard deviation is the US 
system with a 10 nF capacitor, making it the one which will be used for the measurements 
requiring the US system. 
 
Figure 51 – Stage position data comparison for the longitudinal direction for 10 CPs acquired with the US system for 3 
situations: US system without capacitor, US system with a 10 nF capacitor and US system with a 100 nF capacitor. The stage 
total distance was set to 2 cm during an irradiation period of 120 seconds. 
Table 5 – Standard deviation calculated when the stage is stopped for 3 situations: US system without capacitor, US system 
with a 10 nF capacitor and US system with a 100 nF capacitor.  
Standard deviation when the stage is stopped 
Without Capacitor 
With Capacitor 
10 nF 100 nF 
2.06E-02 3.10E-03 3.00E-03 
2.31E-02 3.40E-03 3.50E-03 
2.50E-02 3.50E-03 2.90E-03 
2.13E-02 3.70E-03 4.50E-03 
2.27E-02 2.90E-03 3.30E-03 
2.25E-02 2.80E-03 3.30E-03 
2.10E-02 2.50E-03 2.70E-03 
2.02E-02 3.30E-03 2.40E-03 
2.11E-02 2.40E-03 3.20E-03 
2.24E-02 2.90E-03 3.40E-03 
Mean of the standard deviation  
2.20E-02 3.05E-03 3.22E-03 
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APPENDIX C - NEED OF ADDITIONAL SPATIAL DEGREES OF FREEDOM IN 
SMALL ANIMAL RADIOTHERAPY 
The gantry rotates in the y plane which corresponds to the axial plane. In Figure 52 a) y 
represents the vertical axis, x represents the lateral axis and z represents the longitudinal axis. 
The cranio-caudal direction corresponds to the z axis. The top of the gantry is located in the upper 
intersection of the 3 anatomical planes as represented in Figure 52 b) and the default gantry 
direction rotation is clockwise. Figure 52 c) represents the coronal plane and shows the initial 
reference position and the gantry direction default rotation which is clockwise. 
 
Figure 52 – a) Spherical coordinates. b) The three orthogonal anatomic planes of the rat body and reference points for the 
gantry with respect to the rat body orientation. c) Illustration of the initial reference position for the coronal plane and the 
gantry rotation direction considered in this thesis.  
C.1. Mouse glioblastoma case 
Table 6 – Description of the beams used to simulate the different treatment cases for the mouse glioblastoma case. 
 
Number of 
beams 
Beam # Type Description 
Case 1 2 
1 Static Beam delivered from the top of the gantry 
2 Static Beam delivered from the bottom of the gantry 
Case 2 1 1 Dynamic 360 degrees arc revolution 
Case 3 1 1 Static 
Beam rotated 60 degrees from the axial plane in the 
cranio-caudal direction 
 
 
 
x 
z 
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C.2. Mouse lung tumor case 
Table 7 – Description of the beams used to simulate the different treatment cases for the mouse lung tumor case. 
 
Number of 
beams 
Beam # Type Description 
Case 1 2 
1 Static Beam deviated 9 degrees from the vertical axis 
2 Static Beam deviated 261 degrees from the vertical axis 
Case 2 3 
1 Static 
Beam rotated 30 degrees from the axial plane in the 
cranio-caudal direction 
2 Static 
Beam rotated 40 degrees from the axial plane in the 
cranio-caudal direction 
3 Static 
Beam rotated 50 degrees from the axial plane in the 
cranio-caudal direction 
Case 3 11 
1 Static Beam delivered from the top of the gantry 
2 Static Beam deviated 9 degrees from the vertical axis 
3 Static Beam deviated 151 degrees from the vertical axis 
4 Static Beam deviated 353 degrees from the vertical axis 
5 Static 
Beam rotated 45 degrees from the axial plane in the 
cranio-caudal direction 
6 Static 
Beam rotated 55 degrees from the axial plane in the 
cranio-caudal direction 
7 Static 
Beam delivered in parallel with the corornal plane 
deviated 265 degrres from the inicial reference position 
for the coronal plane 
8 Static 
Beam delivered in parallel with the corornal plane 
deviated 270 degrres from the inicial reference position 
for the coronal plane 
9 Static 
Beam delivered in parallel with the corornal plane 
deviated 275 degrres from the inicial reference position 
for the coronal plane 
10 Static 
Beam delivered in parallel with the corornal plane 
deviated 285 degrres from the inicial reference position 
for the coronal plane 
11 Static 
Beam delivered in parallel with the corornal plane 
deviated 290 degrres from the inicial reference position 
for the coronal plane 
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APPENDIX D - TREATMENT BASED ON STAGE TRANSLATION 
D1. Mouse lung tumor case  
Table 8 – Description of the beams for each stage position used to simulate the different treatment cases for the mouse lung 
tumor case. 
 
Number 
of beams 
Beam # Type 
Number of 
stage 
positions 
Description 
Case 1 2 
1 Static 
1 
Beam delivered from the top of the gantry 
2 Static 
Beam deviated 9 degrees from the 
vertical axis 
Case 2 1 1 Dynamic 316 Beam delivered from the top of the gantry 
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APPENDIX E - SMALL ANIMAL PLATFORM PERFORMANCE BEFORE UPDATE 
Initially the performance of the stage translation using protocols with different numbers of CPs 
was evaluated based on dose distributions. To assess the dose distributions, radiochromic EBT3 
films were used. During the first experiments was discovered that the delivered dose was 
increasing with the number of CPs (Figure 53). To better understand this dose increasing with the 
increasing number of CPs, the US system was used to measure the stage translation distance and 
the irradiation period. The results are presented in Figure 54 and shows an increase of the 
irradiation period when the number of CPs increase. Once the error was found, an update was 
performed to the small animal platform and the error was fixed.  
 
Figure 53 - Dose distribution measured with EBT3 films for 20, 50, 250 and 1000 CPs for a total longitudinal stage translation 
of 2 cm before the small animal platform update. A circular field with a diameter of 10 mm was used for collimation. 
 
Figure 54 - Stage translation in the longitudinal direction for different numbers of CPs before the small animal platform 
update. The stage position was measured with the US system and the total distance was set to 2 cm. 
